ILLUMINA INC, 10-K filed on 2/12/2019
Annual Report
v3.10.0.1
Document and Entity Information Document - USD ($)
shares in Millions, $ in Billions
 12 Months Ended
Dec. 30, 2018
Feb. 08, 2019
Jul. 01, 2018
Document and Entity Information [Abstract]      
Entity Registrant Name Illumina Inc    
Entity Central Index Key 0001110803    
Current Fiscal Year End Date --12-30    
Entity Filer Category Large Accelerated Filer    
Document Type 10-K    
Document Period End Date Dec. 30, 2018    
Document Fiscal Year Focus 2018    
Document Fiscal Period Focus FY    
Amendment Flag false    
Entity Common Stock, Shares Outstanding   147  
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Public Float     $ 35.9
Entity Emerging Growth Company false    
Entity Small Business false    
Entity Shell Company false    
v3.10.0.1
Consolidated Balance Sheets - USD ($)
$ in Millions
Dec. 30, 2018
Dec. 31, 2017
Current assets:    
Cash and cash equivalents $ 1,144 $ 1,225
Short-term investments 2,368 920
Accounts receivable, net 514 411
Inventory 386 333
Prepaid expenses and other current assets 78 91
Total current assets 4,490 2,980
Property and equipment, net 1,075 931
Goodwill 831 771
Intangible assets, net 185 175
Deferred tax assets, net 70 88
Other assets 308 312
Total assets 6,959 5,257
Current liabilities:    
Accounts payable 184 160
Accrued liabilities 513 432
Build-to-suit lease liability   144
Long-term debt, current portion 1,107 10
Total current liabilities 1,804 746
Long-term debt 890 1,182
Other long-term liabilities 359 360
Commitments and contingencies
Redeemable noncontrolling interests 61 220
Stockholders’ equity:    
Preferred stock, $0.01 par value, 10 million shares authorized; no shares issued and outstanding at December 30, 2018 and December 31, 2017 0 0
Common stock, $0.01 par value, 320 million shares authorized; 192 million shares issued and 147 million outstanding at December 30, 2018; 191 million shares issued and 147 million outstanding at December 31, 2017 2 2
Additional paid-in capital 3,290 2,833
Accumulated other comprehensive loss (1) (1)
Retained earnings 3,083 2,256
Treasury stock, 45 million shares and 44 million shares at cost at December 30, 2018 and December 31, 2017, respectively (2,616) (2,341)
Total Illumina stockholders’ equity 3,758 2,749
Noncontrolling interests 87  
Total stockholders’ equity 3,845 2,749
Total liabilities and stockholders’ equity $ 6,959 $ 5,257
v3.10.0.1
Consolidated Balance Sheets (Parenthetical) - $ / shares
shares in Millions
Dec. 30, 2018
Dec. 31, 2017
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized 10 10
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized 320 320
Common stock, shares issued 192 191
Common stock, shares outstanding 147 147
Treasury stock, shares 45 44
v3.10.0.1
Consolidated Statements of Income - USD ($)
shares in Millions, $ in Millions
 12 Months Ended
Dec. 30, 2018
Dec. 31, 2017
Jan. 01, 2017
Revenue:      
Total revenue $ 3,333 $ 2,752 $ 2,398
Cost of revenue:      
Amortization of acquired intangible assets 35 39 43
Total cost of revenue 1,033 926 732
Gross profit 2,300 1,826 1,666
Operating expense:      
Research and development 623 546 504
Selling, general and administrative 794 674 584
Legal contingencies     (9)
Total operating expense 1,417 1,220 1,079
Income from operations 883 606 587
Other income (expense):      
Interest income 44 19 10
Interest expense (57) (37) (33)
Other income (expense), net 24 455 (3)
Total other income (expense), net 11 437 (26)
Income before income taxes 894 1,043 561
Provision for income taxes 112 365 133
Consolidated net income 782 678 428
Add: Net loss attributable to noncontrolling interests 44 48 35
Net income attributable to Illumina stockholders 826 726 463
Net income attributable to Illumina stockholders for earnings per share $ 826 $ 725 $ 454
Earnings per share attributable to Illumina stockholders:      
Basic (in dollars per share) $ 5.63 $ 4.96 $ 3.09
Diluted (in dollars per share) $ 5.56 $ 4.92 $ 3.07
Shares used in computing earnings per share:      
Basic (in shares) 147 146 147
Diluted (in shares) 149 148 148
Product revenue      
Revenue:      
Total revenue $ 2,749 $ 2,289 $ 2,032
Cost of revenue:      
Cost of revenue 738 679 534
Service and other revenue      
Revenue:      
Total revenue 584 463 366
Cost of revenue:      
Cost of revenue $ 260 $ 208 $ 155
v3.10.0.1
Consolidated Statements of Comprehensive Income - USD ($)
$ in Millions
 12 Months Ended
Dec. 30, 2018
Dec. 31, 2017
Jan. 01, 2017
Statement of Comprehensive Income [Abstract]      
Consolidated net income $ 782 $ 678 $ 428
Unrealized loss on available-for-sale debt securities, net of deferred tax     (1)
Total consolidated comprehensive income 782 678 427
Add: Comprehensive loss attributable to noncontrolling interests 44 48 35
Comprehensive income attributable to Illumina stockholders $ 826 $ 726 $ 462
v3.10.0.1
Consolidated Statements of Stockholders' Equity - USD ($)
shares in Millions, $ in Millions
Total
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Loss
Retained Earnings
Treasury Stock
Noncontrolling Interests
Beginning balance (in shares) at Jan. 03, 2016   187       40  
Beginning balance at Jan. 03, 2016 $ 1,849 $ 2 $ 2,498 $ 0 $ 1,022 $ (1,673) $ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income (loss) 449       463   (14)
Unrealized loss on available-for-sale securities, net of deferred tax (1)     (1)      
Issuance of common stock, net of repurchases (in shares)   2       (3)  
Issuance of common stock, net of repurchases (302)   47     $ (349)  
Share-based compensation 129   129        
Net incremental tax benefit related to share-based compensation 87   87        
Adjustment to the carrying value of redeemable noncontrolling interests (21)   (21)        
Vesting of redeemable equity awards (2)   (2)        
Issuance of subsidiary shares in business combination 2   2        
Issuance of treasury stock 3   3        
Contributions from noncontrolling interest owners 80           80
Proceeds from early exercise of equity awards from a subsidiary 7           7
Tax impact of deemed dividend from GRAIL (10)   (10)        
Ending balance (in shares) at Jan. 01, 2017   189       43  
Ending balance at Jan. 01, 2017 2,270 $ 2 2,733 (1) 1,485 $ (2,022) 73
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income (loss) 719       726   (7)
Issuance of common stock, net of repurchases (in shares)   2       (1)  
Issuance of common stock, net of repurchases (248)   71     $ (319)  
Share-based compensation 164   164        
Adjustment to the carrying value of redeemable noncontrolling interests (136)   (136)        
Vesting of redeemable equity awards (13)   (13)        
Cumulative-effect adjustment from adoption of new accounting standard 48   3   45    
Deconsolidation of GRAIL (55)   11       (66)
Ending balance (in shares) at Dec. 31, 2017   191       44  
Ending balance at Dec. 31, 2017 2,749 $ 2 2,833 (1) 2,256 $ (2,341) 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income (loss) 816       826   (10)
Issuance of common stock, net of repurchases (in shares)   1       (1)  
Issuance of common stock, net of repurchases (229)   46     $ (275)  
Share-based compensation 193   193        
Adjustment to the carrying value of redeemable noncontrolling interests 127   127        
Vesting of redeemable equity awards (2)   (2)        
Cumulative-effect adjustment from adoption of new accounting standard 1       1    
Issuance of subsidiary shares in business combination 5           5
Contributions from noncontrolling interest owners 92           92
Issuance of convertible senior notes, net of tax impact 93   93        
Ending balance (in shares) at Dec. 30, 2018   192       45  
Ending balance at Dec. 30, 2018 $ 3,845 $ 2 $ 3,290 $ (1) $ 3,083 $ (2,616) $ 87
v3.10.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 12 Months Ended
Dec. 30, 2018
Dec. 31, 2017
Jan. 01, 2017
Cash flows from operating activities:      
Consolidated net income $ 782 $ 678 $ 428
Adjustments to reconcile net income to net cash provided by operating activities:      
Gain on deconsolidation of GRAIL   (453)  
Depreciation expense 140 110 90
Amortization of intangible assets 39 46 51
Share-based compensation expense 193 164 129
Accretion of debt discount 41 30 30
Deferred income taxes (18) 81 94
Impairment of intangible assets   23  
Other (17) 1 2
Changes in operating assets and liabilities:      
Accounts receivable (105) (26) 3
Inventory (53) (33) (30)
Prepaid expenses and other current assets 5 8 (1)
Other assets (9) (5) (7)
Accounts payable 45 10 (2)
Accrued liabilities 103 81 (24)
Other long-term liabilities (4) 160 16
Net cash provided by operating activities 1,142 875 779
Cash flows from investing activities:      
Purchases of available-for-sale securities (2,859) (742) (895)
Sales of available-for-sale securities 597 322 543
Maturities of available-for-sale securities 860 321 140
Net cash paid for acquisitions (100)   (18)
Proceeds from sale of GRAIL securities   278  
Deconsolidation of GRAIL cash   (52)  
Net purchases of strategic investments (15) (29) (14)
Purchases of property and equipment (296) (310) (260)
Cash paid for intangible assets   (2) (11)
Net cash used in investing activities (1,813) (214) (515)
Cash flows from financing activities:      
Net proceeds from issuance of debt 735 5 5
Common stock repurchases (201) (251) (249)
Proceeds from issuance of common stock 46 71 47
Taxes paid related to net share settlement of equity awards (74) (68) (100)
Payments on financing obligations (4) (9) (66)
Contributions from noncontrolling interest owners 92 79 89
Payments on acquisition related contingent consideration liability   (3) (29)
Proceeds from early exercise of equity awards from a subsidiary     7
Net cash provided by (used in) financing activities 594 (176) (296)
Effect of exchange rate changes on cash and cash equivalents (4) 5 (2)
Net (decrease) increase in cash and cash equivalents (81) 490 (34)
Cash and cash equivalents at beginning of year 1,225 735 769
Cash and cash equivalents at end of year 1,144 1,225 735
Supplemental cash flow information:      
Cash paid for income taxes $ 99 $ 149 $ 60
v3.10.0.1
Organization and Summary of Significant Accounting Policies
 12 Months Ended
Dec. 30, 2018
Accounting Policies [Abstract]  
Organization and Summary of Significant Accounting Policies
Organization and Summary of Significant Accounting Policies

Organization and Business

We are a provider of sequencing- and array-based solutions, serving customers in the research, clinical and applied markets.  Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. Our customers include a broad range of academic, government, pharmaceutical, biotechnology, and other leading institutions around the globe.

Basis of Presentation

The consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles and include our accounts, our wholly-owned subsidiaries, majority-owned or controlled companies, and variable interest entities (VIEs) for which we are the primary beneficiary. All intercompany transactions and balances have been eliminated in consolidation.

We evaluate our ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether we are the primary beneficiary of the VIE. In determining whether we are the primary beneficiary of a VIE and therefore required to consolidate the VIE, we apply a qualitative approach that determines whether we have both (1) the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. We continuously assess whether we are the primary beneficiary of a VIE, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of such VIE. During the year ended December 30, 2018, our consolidated VIE, Helix, received additional cash contributions from us and third-party investors in exchange for voting equity interests in Helix. Therefore, we reassessed and concluded that Helix continued to be a variable interest entity and that we remained the primary beneficiary. During the periods presented, we have not provided any other financial or other support to our VIEs that we were not contractually required to provide.

The equity method is used to account for investments over which we have the ability to exercise significant influence, but not control, over the investee. Such investments are recorded within other assets, and the share of net income or losses of equity investments is recognized on a one quarter lag in other income (expense), net.

Redeemable Noncontrolling Interests

Noncontrolling interests represent the portion of equity (net assets) in Helix, our consolidated but not wholly-owned entity, that is neither directly nor indirectly attributable to us. Noncontrolling interests with embedded contingent redemption features, such as put rights, that are not solely within our control are considered redeemable noncontrolling interests. Redeemable noncontrolling interests are presented outside of stockholders’ equity on the consolidated balance sheets.

Fiscal Year

Our fiscal year is the 52 or 53 weeks ending the Sunday closest to December 31, with quarters of 13 or 14 weeks ending the Sunday closest to March 31, June 30, September 30, and December 31. The years ended December 30, 2018, December 31, 2017, and January 1, 2017 were all 52 weeks.

Reclassifications

Certain prior period amounts have been reclassified to conform to the current period presentation.

Use of Estimates

The preparation of the consolidated financial statements requires that management make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures of contingent assets and liabilities. Actual results could differ from those estimates.
Accounting Pronouncements Adopted in 2018

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). The new standard is based on the principle that revenue should be recognized in an amount that reflects the consideration to which we expect to be entitled in exchange for the transfer of promised goods or services. We adopted Topic 606 using the modified retrospective transition method. The cumulative effect of applying the new revenue standard to all incomplete contracts as of January 1, 2018 was not material and, therefore, did not result in an adjustment to retained earnings. There was no material difference to the consolidated financial statements for the year ended December 30, 2018 due to the adoption of Topic 606.

In January 2016, the FASB issued ASU 2016-01, Financial Instruments - Overall (Subtopic 825-10), which requires equity investments (other than those accounted for under the equity method or those that result in consolidation) to be measured at fair value, with changes in fair value recognized in net income. This standard was effective for us beginning in the first quarter of 2018. Based on our elections, our equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer. This measurement alternative was applied prospectively to such equity securities and did not result in an adjustment to retained earnings.

Accounting Pronouncements Adopted in 2017

In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718), which aims to simplify the accounting for share-based payment transactions, including accounting for income taxes, classification on the statement of cash flows, accounting for forfeitures, and classification of awards as either liabilities or equity. This ASU was effective for us beginning in the first quarter of 2017.

This new standard increases the volatility of net income by requiring excess tax benefits from share-based payment arrangements to be classified as discrete items within the provision for income taxes, rather than recognizing excess tax benefits in additional paid-in capital. Upon adoption in Q1 2017, we recorded $45 million, net, to retained earnings, primarily related to unrealized tax benefits associated with share-based compensation. As a result of the adoption of this new standard, we made an accounting policy election to recognize forfeitures as they occur and no longer estimate expected forfeitures.

In addition, ASU 2016-09 requires that excess income tax benefits from share-based compensation arrangements be classified as cash flow from operations, rather than cash flow from financing activities. We elected to apply the cash flow classification guidance retrospectively and reclassified $91 million from financing activity to operating activity for the year ended January 1, 2017.

Recently Issued Accounting Pronouncements

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842).  The new standard requires lessees to recognize most leases on their balance sheet as lease liabilities with corresponding right-of-use assets and disclose key information about leasing arrangements.  ASU 2016-02 is effective for us beginning in the first quarter of 2019 and will be adopted using a modified retrospective approach by recognizing a cumulative-effect adjustment to the opening balance of retained earnings on December 31, 2018. We will continue to report financial information for fiscal years ending before December 31, 2018 under the current lease accounting standard. 

We elected the standard’s package of practical expedients on adoption, which allows us to carry forward our historical assessment of whether existing agreements contain a lease and the classification of our existing lease agreements as either operating or capital leases (referred to as operating and financing leases in the new standard).  We did not elect the standard’s available hindsight practical expedient on adoption.  The standard also provides practical expedients for ongoing lessee accounting after adoption. We expect to elect the practical expedient to not separate lease and non-lease components for our real-estate leases and will therefore allocate all fixed lease payments, which may include management fees and common-area-maintenance charges, to our operating lease liabilities and corresponding right-of-use assets. 

We have finalized the changes to our systems, processes, policies, and controls for lease accounting, including implementation of a third-party software application, to facilitate our adoption of the lease standard effective December 31, 2018.  We expect the most significant impacts of adoption to result from the recognition of our operating and build-to-suit lease commitments as lease liabilities with corresponding right-of-use assets, and the derecognition of existing assets and liabilities for our build-to-suit arrangements that do not qualify for sale-leaseback accounting.  We currently expect this will result in the net recognition of additional total assets and liabilities of approximately $329 million and $354 million, respectively, and the difference between these amounts will be recorded as a cumulative-effect adjustment to retained earnings upon adoption in the first quarter of 2019.  We also expect the classification of a portion of lease expense for our build-to-suit arrangements to change from interest expense to operating expense going forward.  During the year ended December 30, 2018, the interest portion of lease expense for our build-to-suit arrangements was $13 million.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available-for-sale debt securities. The standard is effective for us beginning in the first quarter of 2020, with early adoption permitted.  We are currently evaluating the expected impact of ASU 2016-13 on our consolidated financial statements.
Concentrations of Risk

We operate in markets that are highly competitive and rapidly changing. Significant technological changes, shifting customer needs, the emergence of competitive products or services with new capabilities, and other factors could negatively impact our operating results. A portion of our customers consist of university and research institutions that management believes are, to some degree, directly or indirectly supported by the United States Government. A significant change in current research funding, particularly with respect to the U.S. National Institutes of Health, could have an adverse impact on future revenues and results of operations.

We are also subject to risks related to our financial instruments, including cash and cash equivalents, investments, and accounts receivable. Most of our cash and cash equivalents as of December 30, 2018 were deposited with U.S. financial institutions, either domestically or with their foreign branches. Our investment policy restricts the amount of credit exposure to any one issuer to 5% of the portfolio or 5% of the total issue size outstanding at the time of purchase and to any one industry sector, as defined by Clearwater Analytics (Industry Sector Report), to 30% of the portfolio at the time of purchase. There is no limit to the percentage of the portfolio that may be maintained in debt securities, U.S. government-sponsored entities, U.S. Treasury securities, and money market funds.

We require customized products and components that currently are available from a limited number of sources. We source certain key products and components included in our products from single vendors.

We perform regular reviews of customer activity and associated credit risks and do not require collateral or enter into netting arrangements. Shipments to customers outside the United States comprised 47%, 45%, and 46% of total revenue for the years ended December 30, 2018, December 31, 2017, and January 1, 2017, respectively. Customers outside the United States represented 44% and 48% of our gross trade accounts receivable balance as of December 30, 2018 and December 31, 2017, respectively.

International sales entail a variety of risks, including currency exchange fluctuations, longer payment cycles, and greater difficulty in accounts receivable collection. We are also subject to general geopolitical risks, such as political, social and economic instability, and changes in diplomatic and trade relations. The risks of international sales are mitigated in part by the extent to which sales are geographically distributed.

Historically, we have not experienced significant credit losses from investments and accounts receivable.

Fair Value Measurements

The fair value of assets and liabilities are based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. We use a fair value hierarchy with three levels of inputs, of which the first two are considered observable and the last unobservable, to measure fair value:

•
Level 1 — Quoted prices in active markets for identical assets or liabilities.
•
Level 2 — Inputs, other than Level 1, that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
•
Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The carrying amounts of financial instruments such as cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable, and accrued liabilities approximate the related fair values due to the short-term maturities of these instruments.

Functional Currency

The U.S. dollar is the functional currency of our international operations. We re-measure foreign subsidiaries’ monetary assets and liabilities to the U.S. dollar and record the net gains or losses resulting from re-measurement in other income (expense), net in the consolidated statements of income.

Acquisitions

All assets acquired and liabilities assumed are measured at fair value as of the acquisition date. We record the excess of purchase price over the aggregate value assigned to the net tangible and identifiable intangible assets acquired as goodwill. Acquired intangible assets other than goodwill are amortized over their useful lives. Post-acquisition adjustments in deferred tax asset valuation allowances and liabilities for uncertain tax positions are recorded in current period income tax expense.

Cash Equivalents and Short-Term Investments

Cash equivalents are comprised of short-term, highly-liquid investments with maturities of 90 days or less at the date of purchase.

Short-term investments consist of debt securities in U.S. government-sponsored entities, corporate debt securities, U.S. Treasury securities, and equity securities. We classify short-term debt investments as available-for-sale at the time of purchase and evaluate such classification as of each balance sheet date. All short-term debt investments are recorded at estimated fair value. Unrealized gains and losses for available-for-sale debt securities are included in accumulated other comprehensive income (loss), a component of stockholders’ equity. We evaluate our debt investments to assess whether those with unrealized loss positions are other than temporarily impaired. Impairments are considered to be other than temporary if they are related to deterioration in credit risk or if it is likely that the securities will be sold before the recovery of their cost basis. Realized gains, losses, and declines in value judged to be other than temporary are determined based on the specific identification method and are recorded in interest income (expense), net in the consolidated statements of income.

Equity investments with readily determinable fair values are classified as current or noncurrent based on the nature of the securities and their availability for use in current operations. All short-term equity investments are recorded at estimated fair value. Unrealized gains and losses for equity securities with readily determinable fair values are recorded in other income (expense), net in the consolidated statements of income.

Accounts Receivable

Trade accounts receivable are recorded at the net invoice value and are not interest-bearing. Receivables are considered past due based on the contractual payment terms. We reserve specific receivables if collectibility is no longer reasonably assured. We also reserve a percentage of our trade receivable balance based on collection history and current economic trends that might impact the level of future credit losses. These reserves are re-evaluated on a regular basis and adjusted as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the reserve.

Inventory

Inventory is stated at the lower of cost or net realizable value, on a first-in, first-out basis. Inventory includes raw materials and finished goods that may be used in the research and development process, and such items are expensed as consumed or expired. Inventory write-downs for slow-moving, excess, and obsolete inventories are estimated based on product life cycles, quality issues, historical experience, and usage forecasts.

Property and Equipment

Property and equipment are stated at cost, subject to review for impairment, and depreciated over the estimated useful lives of the assets, using the straight-line method. Depreciation of leasehold improvements is recorded over the shorter of the lease term or the estimated useful life of the related assets. Amortization of assets that are recorded under capital leases are included in depreciation expense. Maintenance and repairs are expensed as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in operating expense.

Costs incurred to develop internal-use software during the application development stage are recorded as computer software costs, at cost. Costs incurred in the development of such internal-use software, including external direct costs of materials and services and applicable compensation costs of employees devoted to specific software application development, are capitalized. Cost incurred outside of the application development stage are expensed as incurred.

The estimated useful lives of the major classes of property and equipment are generally as follows:
 
Estimated Useful Lives
Buildings and leasehold improvements
4 to 20 years
Machinery and equipment
3 to 5 years
Computer hardware and software
3 to 7 years
Furniture and fixtures
7 years


Leases

Leases are reviewed and classified as capital or operating at their inception. When we are involved in the construction of leased assets, we evaluate whether we are the accounting owner during the construction period. For leases where we are the deemed accounting owner during the construction period, we record project construction costs paid or reimbursed by the landlord as construction in progress and a corresponding build-to-suit lease liability. For operating leases, rent expense is recorded on a straight-line basis over the term of the lease, which includes the construction build-out period and lease extension periods, if appropriate. The difference between rent payments and straight-line rent expense is recorded as deferred rent in accrued liabilities and other long-term liabilities. Lease incentives are amortized on a straight-line basis over the lease term as a reduction to rent expense.
Goodwill, Intangible Assets and Other Long-Lived Assets

Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired in an acquisition. Goodwill is reviewed for impairment at least annually during the second quarter, or more frequently if an event occurs indicating the potential for impairment. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair values of our reporting units are less than the carrying amounts, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair values of our reporting units are less than the carrying amounts, then no additional assessment is deemed necessary. Otherwise, we proceed to perform the two-step test for goodwill impairment. The first step involves comparing the estimated fair values of the reporting units with the carrying values, including goodwill. If the carrying amounts of the reporting units exceed the fair values, the second step of the goodwill impairment test is performed to determine the amount of loss, which involves comparing the implied fair values of the goodwill to the carrying values of the goodwill. We may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the first step of the goodwill impairment test. We performed the annual assessment for goodwill impairment in the second quarter of 2018, noting no impairment.

Our identifiable intangible assets are typically comprised of acquired core technologies, licensed technologies, customer relationships, license agreements, and trade names. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets’ respective estimated useful lives.

We perform regular reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to the net book value, significant changes in the ability of a particular asset to generate positive cash flows for our strategic business objectives, and the pattern of utilization of a particular asset.

During the year ended December 31, 2017, we performed a recoverability test when the planned use of a finite-lived acquired intangible asset changed, resulting in an impairment charge of $18 million recorded in cost of product revenue. Also, during the year ended December 31, 2017, we recorded a $5 million impairment charge of in-process research and development as the project had no future alternative use. Such impairments were recorded within the Core Illumina reportable segment. See further discussion of our segments in note “10. Segment Information and Geographic Data.”

Derivatives

We are exposed to foreign exchange rate risks in the normal course of business. We enter into foreign exchange contracts to manage foreign currency risks related to monetary assets and liabilities that are denominated in currencies other than the U.S. dollar. These foreign exchange contracts are carried at fair value in other current assets or accrued liabilities and are not designated as hedging instruments. Changes in the value of the derivatives are recognized in other income (expense), net, along with the re-measurement gain or loss on the foreign currency denominated assets or liabilities.

As of December 30, 2018, we had foreign exchange forward contracts in place to hedge exposures in the euro, Japanese yen, Australian dollar, and Canadian dollar. As of December 30, 2018, and December 31, 2017, the total notional amounts of outstanding forward contracts in place for foreign currency purchases was $122 million and $88 million, respectively.

Warranties

We generally provide a one-year warranty on instruments. Additionally, a warranty on consumables is provided through the expiration date, which generally ranges from six to twelve months after the manufacture date. At the time revenue is recognized, an accrual is established for estimated warranty expenses based on historical experience as well as anticipated product performance. We periodically review the warranty reserve for adequacy and adjust the warranty accrual, if necessary, based on actual experience and estimated costs to be incurred. Warranty expense is recorded as a component of cost of product revenue.

Revenue Recognition

Our revenue is generated primarily from the sale of products and services. Product revenue primarily consists of sales of instruments and consumables used in genetic analysis. Service and other revenue primarily consists of revenue generated from genotyping and sequencing services and instrument service contracts.

We recognize revenue when control of our products and services is transferred to our customers in an amount that reflects the consideration we expect to receive from our customers in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. We consider a performance obligation satisfied once we have transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service.

Revenue from product sales is recognized generally upon delivery to the end customer, which is when control of the product is deemed to be transferred. Invoicing typically occurs upon shipment and payment is typically due within 60 days from invoice. In instances where right of payment or transfer of title is contingent upon the customer’s acceptance of the product, revenue is deferred until all acceptance criteria have been met. Revenue from instrument service contracts is recognized as the services are rendered, typically evenly over the contract term. Revenue from genotyping and sequencing services is recognized when earned, which is generally at the time the genotyping or sequencing analysis data is made available to the customer.

Revenue is recorded net of discounts, distributor commissions, and sales taxes collected on behalf of governmental authorities. Employee sales commissions are recorded as selling, general and administrative expenses when incurred as the amortization period for such costs, if capitalized, would have been one year or less.

We regularly enter into contracts with multiple performance obligations. Revenue recognition for contracts with multiple deliverables is based on the separate satisfaction of each distinct performance obligation within the contract.  Most performance obligations are generally satisfied within a short time frame, approximately three to six months, after the contract execution date. As of December 30, 2018, the aggregate amount of the transaction price allocated to remaining performance obligations was $909 million, of which approximately 80% is expected to be converted to revenue through 2019, with the remainder thereafter.

The contract price is allocated to each performance obligation in proportion to its standalone selling price. We determine our best estimate of standalone selling price using average selling prices over a rolling 12-month period coupled with an assessment of current market conditions. If the product or service has no history of sales or if the sales volume is not sufficient, we rely upon prices set by management, adjusted for applicable discounts.

Contract liabilities, which consist of deferred revenue and customer deposits, as of December 30, 2018 and December 31, 2017 were $206 million and $181 million, respectively, of which the short-term portions of $175 million and $150 million, respectively, were recorded in accrued liabilities and the remaining long-term portions were recorded in other long-term liabilities. Revenue recorded during the year ended December 30, 2018 included $146 million of previously deferred revenue that was included in contract liabilities as of December 31, 2017. Contract assets as of December 30, 2018 and December 31, 2017 were not material.

In certain markets, products and services are sold to customers through distributors. In most sales through distributors, the product is delivered directly to customers by us. The terms of sales transactions through distributors are consistent with the terms of direct sales to customers.

The following table represents revenue by source (in millions):
 
Years Ended
 
December 30,
2018
 
December 31,
2017
 
January 1,
2017
 
Sequencing
 
Microarray
 
Total
 
Sequencing
 
Microarray
 
Total
 
Sequencing
 
Microarray
 
Total
Consumables
$
1,806

 
$
350

 
$
2,156

 
$
1,468

 
$
285

 
$
1,753

 
$
1,271

 
$
272

 
$
1,543

Instruments
532

 
37

 
569

 
484

 
31

 
515

 
450

 
19

 
469

Other product
21

 
3

 
24

 
19

 
2

 
21

 
18

 
2

 
20

Total product revenue
2,359

 
390

 
2,749

 
1,971

 
318

 
2,289

 
1,739

 
293

 
2,032

Service and other revenue
416

 
168

 
584

 
322

 
141

 
463

 
277

 
89

 
366

Total revenue
$
2,775

 
$
558

 
$
3,333

 
$
2,293

 
$
459

 
$
2,752

 
$
2,016

 
$
382

 
$
2,398



Revenue related to our Consolidated VIEs is included in sequencing service and other revenue.

The majority of our revenue consists of sales of consumables and instruments. We also perform various services for our customers. For the years ended December 30, 2018, December 31, 2017, and January 1, 2017, consumable sales represented 65%, 64%, and 64%, respectively, of total revenue; instrument sales represented 17%, 19%, and 20%, respectively, of total revenue; and services represented 18%, 17%, and 15%, respectively, of total revenue. Our customers include leading genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. We had no customers that provided more than 10% of total revenue in the years ended December 30, 2018, December 31, 2017, and January 1, 2017.

The following table represents revenue by geographic area, based on region of destination (in millions):
 
Years Ended
 
December 30,
2018
 
December 31,
2017
 
January 1,
2017
Americas (1)
$
1,864

 
$
1,585

 
$
1,367

Europe, Middle East, and Africa
851

 
653

 
575

Greater China (2)
365

 
292

 
—

Asia-Pacific
253

 
222

 
456

Total revenue
$
3,333

 
$
2,752

 
$
2,398

____________________________________
(1) Revenue for the Americas region included United States revenue of $1,779 million, $1,511 million, and $1,294 million for the years ended December 30, 2018, December 31, 2017, and January 1, 2017, respectively.
(2) Revenue for the Greater China region, which includes China, Taiwan, and Hong Kong, is included in the Asia-Pacific region for the year ended January 1, 2017.

Share-Based Compensation

Share-based compensation expense is incurred related to restricted stock and Employee Stock Purchase Plan (ESPP).

Restricted stock units (RSU) and performance stock units (PSU) are both considered restricted stock. The fair value of restricted stock is determined by the closing market price of our common stock on the date of grant. Share-based compensation expense is recognized based on the fair value on a straight-line basis over the requisite service periods of the awards. PSU represents a right to receive a certain number of shares of common stock based on the achievement of corporate performance goals and continued employment during the vesting period. At each reporting period, we reassess the probability of the achievement of such corporate performance goals and any additional expenses resulting from an adjustment in the estimated shares to be released are treated as a cumulative catch-up in the period of adjustment.

The Black-Scholes-Merton option-pricing model is used to estimate the fair value of stock purchased under our ESPP. The model assumptions include expected volatility, term, dividends, and the risk-free interest rate. The expected volatility is determined by equally weighing the historical and implied volatility of our common stock. The historical volatility is generally commensurate with the estimated expected term, adjusted for the impact of unusual fluctuations and other relevant factors. The implied volatility is calculated from the implied market volatility of exchange-traded call options on our common stock. The expected term is based on historical forfeiture experience and the terms and conditions of the ESPP. The expected dividend yield is determined to be 0% given that we have never declared or paid cash dividends on our common stock and do not anticipate paying such cash dividends. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected term of the share-based awards.

Forfeitures are accounted for as incurred as reversal of any share-based compensation expense related to awards that will not vest.

Shipping and Handling Expenses

Shipping and handling expenses are included in cost of product revenue.

Research and Development

Research and development expenses include personnel expenses, contractor fees, license fees, facilities costs, and utilities. Expenditures relating to research and development are expensed in the period incurred.

Advertising Costs

Advertising costs are expensed as incurred. Advertising costs were $38 million, $30 million, and $20 million for the years ended December 30, 2018, December 31, 2017, and January 1, 2017, respectively.

Income Taxes

The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for the expected future tax benefit to be derived from tax loss and credit carryforwards. Deferred tax assets and liabilities are determined using the enacted tax rates in effect for the years in which those tax assets are expected to be realized. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date.

Deferred tax assets are regularly assessed to determine the likelihood they will be recovered from future taxable income. A valuation allowance is established when we believe it is more likely than not the future realization of all or some of a deferred tax asset will not be achieved. In evaluating the ability to recover deferred tax assets within the jurisdiction which they arise, we consider all available positive and negative evidence. Factors reviewed include the cumulative pre-tax book income for the past three years, scheduled reversals of deferred tax liabilities, history of earnings and reliable forecasting, projections of pre-tax book income over the foreseeable future, and the impact of any feasible and prudent tax planning strategies.

The impact of a tax position is recognized in the consolidated financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected in income tax expense.

Earnings per Share

Basic earnings per share attributable to Illumina stockholders is computed based on the weighted average number of common shares outstanding during the period. Diluted earnings per share attributable to Illumina stockholders is computed based on the sum of the weighted average number of common shares and potentially dilutive common shares outstanding during the period. Per-share earnings of our VIEs are included in the consolidated basic and diluted earnings per share computations based on our share of the VIE’s securities.

Potentially dilutive common shares consist of shares issuable under convertible senior notes and equity awards. Convertible senior notes have a dilutive impact when the average market price of our common stock exceeds the applicable conversion price of the respective notes. Potentially dilutive common shares from equity awards are determined using the average share price for each period under the treasury stock method. In addition, proceeds from exercise of equity awards and the average amount of unrecognized compensation expense for equity awards are assumed to be used to repurchase shares.

The following table presents the calculation of weighted average shares used to calculate basic and diluted earnings per share (in millions):
 
Years Ended
 
December 30,
2018
 
December 31,
2017
 
January 1,
2017
Weighted average shares outstanding
147

 
146

 
147

Effect of potentially dilutive common shares from:
 
 
 
 
 
Convertible senior notes
1

 
—

 
—

Equity awards
1

 
2

 
1

Weighted average shares used in calculating diluted earnings per share
149

 
148

 
148



Accumulated Other Comprehensive Loss

The components of accumulated other comprehensive loss were as follows (in millions):
 
December 30,
2018
 
December 31,
2017
Foreign currency translation adjustments
$
1

 
$
1

Unrealized loss on available-for-sale debt securities, net of deferred tax
(2
)
 
(2
)
Total accumulated other comprehensive loss
$
(1
)
 
$
(1
)
v3.10.0.1
Balance Sheet Account Details
 12 Months Ended
Dec. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Balance Sheet Account Details
Balance Sheet Account Details

Investments

Debt Securities

Available-for-sale debt securities, included in short-term investments, consisted of the following (in millions):
 
December 30, 2018
 
December 31, 2017
 
Amortized
Cost
 
Gross
Unrealized
Losses
 
Gross
Unrealized
Gains
 
 
Estimated
Fair Value
 
 Amortized
Cost
 
Gross
Unrealized
Losses
 
 
Estimated
Fair Value
Debt securities in government-sponsored entities
$
21

 
$
—

 
$
—

 
$
21

 
$
67

 
$
—

 
$
67

Corporate debt securities
1,060

 
(2
)
 
—

 
1,058

 
423

 
(2
)
 
421

U.S. Treasury securities
1,250

 
(1
)
 
1

 
1,250

 
433

 
(1
)
 
432

Total
$
2,331

 
$
(3
)
 
$
1

 
$
2,329

 
$
923

 
$
(3
)
 
$
920



Contractual maturities of available-for-sale debt securities, as of December 30, 2018, were as follows (in millions):
 
Estimated Fair Value
Due within one year
$
1,618

After one but within five years
711

Total
$
2,329


We have the ability, if necessary, to liquidate any of our cash equivalents and short-term investments to meet our liquidity needs in the next 12 months. Accordingly, those investments with contractual maturities greater than one year from the date of purchase are classified as short-term on the accompanying consolidated balance sheets.

Equity Securities

Our equity securities are strategic investments primarily in privately held companies.

The carrying values of our non-marketable equity securities without readily determinable market values are initially measured at cost and adjusted to fair value for observable transactions for identical or similar investments of the same issuer or impairment. Unrealized gains and losses on non-marketable equity securities are recognized in other income (expense), net. As of December 30, 2018 and December 31, 2017, the aggregate carrying amounts of our non-marketable equity investments without readily determinable fair values were $231 million and $250 million, respectively, included in other assets. The decline was primarily due to the reclassification of an equity security that became marketable in 2018 to short-term investments.

Our marketable equity security is measured at fair value. Unrealized gains and losses are recognized in other income (expense), net. As of December 30, 2018, the fair value of our marketable equity investment was $39 million included in short-term investments. This included an unrealized gain of $21 million recorded in other income (expense), net during the year ended December 30, 2018.

Our equity investments are assessed for impairment quarterly. Impairment losses, equal to the difference between the carrying value and the fair value of the investment, are recorded in other income (expense), net. No material impairment losses were recorded during the years ended December 30, 2018, December 31, 2017, and January 1, 2017.

Revenue recognized from transactions with our strategic equity investees was $143 million, $127 million, and $56 million for the years ended December 30, 2018, December 31, 2017, and January 1, 2017, respectively.

Venture Fund

We invest in a venture capital investment fund (the Fund) with a capital commitment of $100 million that is callable through April 2026, of which $69 million remained as of December 30, 2018. Our investment in the Fund is accounted for as an equity-method investment. The carrying amounts of the Fund, included in other assets, were $29 million and $16 million as of December 30, 2018 and December 31, 2017, respectively.

Accounts Receivable

Accounts receivable, net consisted of the following (in millions):
 
December 30,
2018
 
December 31,
2017
Trade accounts receivable, gross
$
516

 
$
414

Allowance for doubtful accounts
(2
)
 
(3
)
Total accounts receivable, net
$
514

 
$
411



Inventory

Inventory consisted of the following (in millions):
 
December 30,
2018
 
December 31,
2017
Raw materials
$
117

 
$
93

Work in process
218

 
188

Finished goods
51

 
52

Total inventory
$
386

 
$
333



Property and Equipment

Property and equipment, net consisted of the following (in millions):
 
December 30,
2018
 
December 31,
2017
Leasehold improvements
$
567

 
$
331

Machinery and equipment
382

 
316

Computer hardware and software
217

 
185

Furniture and fixtures
45

 
34

Buildings
285

 
155

Construction in progress
100

 
326

Total property and equipment, gross
1,596

 
1,347

Accumulated depreciation
(521
)
 
(416
)
Total property and equipment, net
$
1,075

 
$
931



Property and equipment, net included non-cash expenditures of $35 million, $117 million and $220 million for the years ended December 30, 2018, December 31, 2017 and January 1, 2017, respectively, which were excluded from the consolidated statements of cash flows. Such non-cash expenditures included $18 million, $79 million and $193 million recorded under build-to-suit lease accounting for the years ended December 30, 2018, December 31, 2017 and January 1, 2017, respectively.

Accrued Liabilities

Accrued liabilities consisted of the following (in millions):
 
December 30,
2018
 
December 31,
2017
Contract liabilities, current portion
$
175

 
$
150

Accrued compensation expenses
193

 
177

Accrued taxes payable
82

 
50

Other, including warranties (a)
63

 
55

Total accrued liabilities
$
513

 
$
432



(a) Changes in the reserve for product warranties from January 3, 2016 through December 30, 2018 were as follows (in millions):
 
Warranty Reserve
Balance as of January 3, 2016
$
17

Additions charged to cost of revenue
21

Repairs and replacements
(25
)
Balance as of January 1, 2017
13

Additions charged to cost of revenue
26

Repairs and replacements
(22
)
Balance as of December 31, 2017
17

Additions charged to cost of revenue
27

Repairs and replacements
(25
)
Balance as of December 30, 2018
$
19



Investments in Consolidated Variable Interest Entities

Helix Holdings I, LLC

In July 2015, we obtained a 50% voting equity ownership interest in Helix Holdings I, LLC (Helix), a limited liability company formed with unrelated third-party investors to pursue the development and commercialization of a marketplace for consumer genomics. We determined that Helix is a VIE as the holders of the at-risk equity investments as a group lack the power to direct the activities of Helix that most significantly impact Helix’s economic performance. Additionally, we determined that we have (a) unilateral power over one of the activities that most significantly impacts the economic performance of Helix through its contractual arrangements and no one individual party has unilateral power over the remaining significant activities of Helix and (b) the obligation to absorb losses of and the right to receive benefits from Helix that are potentially significant to Helix. As a result, we are deemed to be the primary beneficiary of Helix and are required to consolidate Helix.

As contractually committed, in July 2015, we contributed certain perpetual licenses, instruments, intangibles, initial laboratory setup, and discounted supply terms in exchange for voting equity interests in Helix. Such contributions were recorded at their historical basis as they remained within our control. Helix is financed through cash contributions made by us and the third-party investors in exchange for voting equity interests in Helix. During the year ended December 30, 2018, we made additional investments of $100 million in exchange for voting equity interests in Helix. As of December 30, 2018, the noncontrolling shareholders and Illumina each held 50% of Helix’s outstanding voting equity interests.

Certain noncontrolling Helix investors may require us to redeem certain noncontrolling interests in cash at the then approximate redemption fair market value. Such redemption right is exercisable at the option of certain noncontrolling interest holders after January 1, 2021, provided that a bona fide pursuit of the sale of Helix has occurred and an initial public offering of Helix has not been completed. As the contingent redemption is outside of our control, the redeemable noncontrolling interests in Helix are classified outside of stockholders’ equity on the accompanying consolidated balance sheets. The balance of the redeemable noncontrolling interests is reported at the greater of its carrying value after receiving its allocation of Helix’s profits and losses or its estimated redemption value at each reporting date. The fair value of the redeemable noncontrolling interests is considered a Level 3 instrument.

As of December 30, 2018, the accompanying consolidated balance sheet included $127 million of cash, cash equivalents, and short-term investments attributable to Helix that will be used to settle its respective obligations and will not be available to settle obligations of Illumina. The remaining assets and liabilities of Helix were not significant to our financial position as of December 30, 2018. Helix had an immaterial impact on our consolidated statements of income and cash flows for the year ended December 30, 2018.

GRAIL, Inc.

In 2016, we obtained a majority equity ownership interest in GRAIL, a company formed with unrelated third-party investors to develop a blood test for early-stage cancer detection. At that time, we determined that GRAIL was a VIE as the entity lacked sufficient equity to finance its activities without additional support. Additionally, we determined that we were the primary beneficiary of GRAIL and were required to consolidate GRAIL. On February 28, 2017, GRAIL completed the initial close of its Series B preferred stock financing, we ceased to have a controlling financial interest in GRAIL, and our equity ownership was reduced from 52% to 19%. Additionally, our voting interest was reduced to 13% and we no longer had representation on GRAIL’s board of directors. As a result, we deconsolidated GRAIL’s financial statements effective February 28, 2017 and recorded a pretax gain on deconsolidation of $453 million in other income (expense), net, of which $159 million related to the remeasurement of our retained equity interest to its fair value. The fair value measurement of our remaining interest was derived using the market approach. Significant estimates and assumptions required for this valuation included, but were not limited to, various Black-Scholes option-pricing model assumptions as of the date of deconsolidation and estimated discounts for lack of marketability related to the equity securities. These unobservable inputs, which represent a Level 3 measurement, are supported by little or no market activity and reflect our own assumptions in measuring fair value. The operations of GRAIL up to February 28, 2017, the date of deconsolidation, were included in the accompanying consolidated statements of income for the years ended December 31, 2017 and January 1, 2017. During these periods, we absorbed approximately 50% of GRAIL’s losses based upon our proportional ownership of GRAIL’s common stock.

The carrying value of our investment recorded in other assets was $189 million and $185 million as of December 30, 2018 and December 31, 2017, respectively.

Redeemable Noncontrolling Interests

The activity of the redeemable noncontrolling interests from January 3, 2016 through December 30, 2018 was as follows (in millions):
 
Redeemable Noncontrolling Interests
Balance as of January 3, 2016
$
33

Cash contributions
9

Vesting of redeemable equity awards
2

Net loss attributable to noncontrolling interests
(21
)
Adjustment up to the redemption value
21

Balance as of January 1, 2017
44

Amount released from escrow
79

Vesting of redeemable equity awards
13

Net loss attributable to noncontrolling interests
(41
)
Adjustment up to the redemption value
136

Deconsolidation of GRAIL
(11
)
Balance as of December 31, 2017
220

Vesting of redeemable equity awards
2

Net loss attributable to noncontrolling interests
(34
)
Adjustment down to the redemption value
(127
)
Balance as of December 30, 2018
$
61
v3.10.0.1
Intangible Assets, Goodwill, and Acquisitions
 12 Months Ended
Dec. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets, Goodwill, and Acquisitions
Intangible Assets, Goodwill, and Acquisitions

Intangible assets, excluding goodwill, include acquired licensed and core technologies, customer relationships, license agreements, and trade name. Amortization for intangible assets is generally recorded on a straight-line basis over their useful lives.
  
Identifiable intangible assets consisted of the following (in millions):
 
December 30, 2018
 
December 31, 2017
 
Gross
Carrying
Amount
 
Accumulated
Amortization
 
Intangibles,
Net
 
Gross
Carrying
Amount
 
Accumulated
Amortization
 
Intangibles,
Net
Licensed technologies
$
95

 
$
(83
)
 
$
12

 
$
95

 
$
(74
)
 
$
21

Core technologies
331

 
(172
)
 
159

 
300

 
(161
)
 
139

Customer relationships
32

 
(27
)
 
5

 
32

 
(25
)
 
7

License agreements
14

 
(9
)
 
5

 
14

 
(8
)
 
6

Trade name
9

 
(5
)
 
4

 
7

 
(5
)
 
2

Total intangible assets, net
$
481

 
$
(296
)
 
$
185

 
$
448

 
$
(273
)
 
$
175



The estimated annual amortization of intangible assets for the next five years is shown in the following table (in millions). Actual amortization expense to be reported in future periods could differ from these estimates as a result of acquisitions, divestitures, and asset impairments, among other factors.
 
Estimated Annual Amortization
2019
$
37

2020
30

2021
26

2022
22

2023
20

Thereafter
50

Total
$
185



Changes to goodwill from January 1, 2017 through December 30, 2018 were as follows (in millions):
 
Goodwill
Balance as of January 1, 2017
$
776

GRAIL deconsolidation
(5
)
Balance as of December 31, 2017
771

Acquisitions
60

Balance as of December 30, 2018
$
831



On May 14, 2018, we acquired Edico Genome, a provider of data analysis acceleration solutions for next-generation sequencing (NGS) for total cash consideration of $100 million, net of cash acquired. As a result of this transaction, we recorded $56 million as goodwill within the Core Illumina reportable segment. In addition, we recorded developed technology of $45 million and a trade name of $1 million, with useful lives of 10 and 3 years, respectively.

On November 1, 2018, we entered into an Agreement and Plan of Merger (the Merger Agreement) to acquire Pacific Biosciences of California, Inc. (PacBio) for an all-cash price of approximately $1.2 billion (or $8.00 per share). The transaction, which is expected to close mid-2019, is subject to certain customary closing conditions, including PacBio shareholder approval and the receipt of certain required antitrust approvals. The Merger Agreement contains certain termination rights and provides that, upon termination of the Merger Agreement under specified circumstances, including but not limited to, a termination of the Merger Agreement in connection with PacBio accepting a superior offer or due to the withdrawal by PacBio’s board of directors of its recommendation of the merger, PacBio will pay us a cash termination fee of $43 million. In certain other circumstances related to antitrust approvals, we may be required to pay PacBio a termination fee of $98 million assuming the other closing conditions not related to antitrust or competition laws have been satisfied.
v3.10.0.1
Fair Value Measurements
 12 Months Ended
Dec. 30, 2018
Fair Value Disclosures [Abstract]  
Fair Value Measurements
Fair Value Measurements

The following table presents the hierarchy for assets and liabilities measured at fair value on a recurring basis as of December 30, 2018 and December 31, 2017 (in millions):
 
December 30, 2018
 
December 31, 2017
 
Level 1
 
Level 2
 
Level 3
 
Total
 
Level 1
 
Level 2
 
Level 3
 
Total
Assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Money market funds (cash equivalents)
$
832

 
$
—

 
$
—

 
$
832

 
$
957

 
$
—

 
$
—

 
$
957

Debt securities in government-sponsored entities
—

 
21

 
—

 
21

 
—

 
67

 
—

 
67

Corporate debt securities
—

 
1,058

 
—

 
1,058

 
—

 
421

 
—

 
421

U.S. Treasury securities
1,250

 
—

 
—

 
1,250

 
432

 
—

 
—

 
432

Marketable equity security
39

 
—

 
—

 
39

 
—

 
—

 
—

 
—

Deferred compensation plan assets
—

 
34

 
—

 
34

 
—

 
35

 
—

 
35

Total assets measured at fair value
$
2,121

 
$
1,113

 
$
—

 
$
3,234

 
$
1,389

 
$
523

 
$
—

 
$
1,912

Liabilities:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Deferred compensation plan liability
$
—

 
$
33

 
$
—

 
$
33

 
—

 
$
33

 
$
—

 
$
33



We hold available-for-sale securities that consist of highly-liquid, investment-grade debt securities. We consider information provided by our investment accounting and reporting service provider in the measurement of fair value of our debt securities. The investment service provider provides valuation information from an industry-recognized valuation service. Such valuations may be based on trade prices in active markets for identical assets or liabilities (Level 1 inputs) or valuation models using inputs that are observable either directly or indirectly (Level 2 inputs), such as quoted prices for similar assets or liabilities, yield curve, volatility factors, credit spreads, default rates, loss severity, current market and contractual prices for the underlying instruments or debt, broker and dealer quotes, as well as other relevant economic measures. Our deferred compensation plan assets consist primarily of investments in life insurance contracts carried at cash surrender value, which reflects the net asset value of the underlying publicly traded mutual funds. We perform control procedures to corroborate the fair value of our holdings, including comparing valuations obtained from our investment service provider to valuations reported by our asset custodians, validating pricing sources and models, and reviewing key model inputs, if necessary.
v3.10.0.1
Debt and Other Commitments
 12 Months Ended
Dec. 30, 2018
Debt Disclosure [Abstract]  
Debt and Other Commitments
Debt and Other Commitments

Summary of debt obligations

Debt obligations consisted of the following (dollars in millions):
 
December 30,
2018
 
December 31,
2017
Principal amount of 2023 Notes outstanding
$
750

 
$
—

Principal amount of 2021 Notes outstanding
517

 
517

Principal amount of 2019 Notes outstanding
633

 
633

Unamortized discount of liability component of convertible senior notes
(175
)
 
(75
)
       Net carrying amount of liability component of convertible senior notes
1,725

 
1,075

Obligations under financing leases
269

 
113

Other
3

 
4

Less: current portion
(1,107
)
 
(10
)
       Long-term debt
$
890

 
$
1,182

Carrying value of equity component of convertible senior notes, net of debt issuance costs
$
287

 
$
161

Fair value of convertible senior notes outstanding (Level 2)
$
2,222

 
$
1,305

Weighted average remaining amortization period of discount on the liability component of convertible senior notes
3.9 years

 
2.8 years



Convertible Senior Notes

0% Convertible Senior Notes due 2023 (2023 Notes)

On August 21, 2018, we issued $750 million aggregate principal amount of convertible senior notes due 2023 (2023 Notes). The net proceeds from the issuance, after deducting the offering expenses payable by us, were $735 million. The 2023 Notes carry no coupon interest and mature on August 15, 2023.

The 2023 Notes will be convertible into cash, shares of our common stock or a combination of cash and shares of our common stock, at our election, based on an initial conversion rate, subject to adjustment, of 2.1845 shares of common stock per $1,000 principal amount of notes (which represents an initial conversion price of approximately $457.77 per share of common stock), only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on September 30, 2018 (and only during such calendar quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price in effect on each applicable trading day; (2) during the five business day period after any 10 consecutive trading day period (the “measurement period”) in which the trading price per $1,000 principal amount of 2023 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day; (3) if we call any or all of the notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or (4) upon the occurrence of specified corporate events described in the indenture. Regardless of the foregoing circumstances, the holders may convert their notes on or after May 15, 2023 until August 11, 2023.

It is our intent and policy to settle conversions through combination settlement; this involves repayment of an amount of cash equal to the “principal amount” and delivery of the “share amount” in excess of the conversion value over the principal amount in shares of common stock. In general, for each $1,000 in principal, the “principal amount” of cash upon settlement is defined as the lesser of $1,000 and the conversion value during the 20-day observation period. The conversion value is the sum of the daily conversion value, which is the product of the effective conversion rate divided by 20 days and the daily volume weighted average price (VWAP) of our common stock. The “share amount” is the cumulative “daily share amount” during the observation period, which is calculated by dividing the daily VWAP into the difference between the daily conversion value (i.e., conversion rate x daily VWAP) and $1,000.

We may redeem for cash all or any portion of the 2023 Notes, at our option, on or after August 20, 2021 if the last reported sale price of our common stock has been at least 130% of the conversion price then in effect (currently $595.10) for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide notice of redemption at a redemption price equal to 100% of the principal amount of the notes to be redeemed, plus any accrued and unpaid special interest to, but excluding, the redemption date.
 
The 2023 Notes are accounted for in accordance with authoritative guidance for convertible debt instruments that may be settled in cash upon conversion. The guidance requires the carrying amount of the liability component to be estimated by estimating the fair value of a similar liability that does not have an associated conversion feature. Because we have no outstanding non-convertible public debt, we determined that market-traded senior, unsecured corporate bonds represent a similar liability without a conversion option. Based on market data available for publicly traded, senior, unsecured corporate bonds issued by companies in our industry, and with similar maturities to the 2023 Notes, we estimated an implied interest rate of 3.7%, assuming no conversion option. Assumptions used in the estimate represent what market participants would use in pricing the liability component, including market interest rates, credit standing, and yield curves, all of which are defined as Level 2 observable inputs. The estimated implied interest rate was applied to the 2023 Notes, which resulted in a fair value of the liability component in aggregate of $624 million upon issuance, calculated as the present value of implied future payments based on the $750 million aggregate principal amount. The $126 million difference ($93 million, net of tax) between the aggregate principal amount of $750 million and the estimated fair value of the liability component was recorded in additional paid-in capital as the 2023 Notes are not considered redeemable.

As a policy election under applicable guidance related to the calculation of diluted net income per share, we have elected the combination settlement method as our stated settlement policy and apply the treasury stock method in the calculation of the potential dilutive impact of the 2023 Notes on net income per share each period. The 2023 Notes were not convertible as of December 30, 2018 and had no dilutive impact during the fiscal year ended December 30, 2018. If the 2023 Notes were converted as of December 30, 2018, the if-converted value would not exceed the principal amount.

0% Convertible Senior Notes due 2019 (2019 Notes) and 0.5% Convertible Senior Notes due 2021 (2021 Notes)

In June 2014, we issued $633 million aggregate principal amount of convertible senior notes due 2019 (2019 Notes) and $517 million aggregate principal amount of convertible senior notes due 2021 (2021 Notes). The net proceeds from the issuance, after deducting the offering expenses payable by us, were $1,132 million. The 2019 Notes carry no coupon interest and mature on June 15, 2019. We pay 0.5% interest per annum on the principal amount of the 2021 Notes, payable semiannually in arrears in cash on June 15 and December 15 of each year, beginning on December 15, 2014. The 2021 Notes mature on June 15, 2021.

Both the 2019 and 2021 Notes will be convertible into cash, shares of common stock, or a combination of cash and shares of common stock, at our election, based on an initial conversion rate, subject to adjustment, of 3.9318 shares per $1,000 principal amount of the notes (which represents an initial conversion price of approximately $254.34 per share), only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending September 30, 2014 (and only during such calendar quarter), if the last reported sale price of our common stock for 20 or more trading days in the period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter exceeds 130% of the applicable conversion price in effect on the last trading day of the immediately preceding calendar quarter; (2) during the five business day period after any 10 consecutive trading day period (the “measurement period”) in which the trading price per 2019 and 2021 Notes for each day of such measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day; or (3) upon the occurrence of specified events described in the indenture for the 2019 and 2021 Notes. Regardless of the foregoing circumstances, the holders may convert their notes on or after March 15, 2019 until June 13, 2019 for the 2019 Notes and March 15, 2021 until June 11, 2021 for the 2021 Notes.

It is our intent and policy to settle conversions through combination settlement; this involves repayment of an amount of cash equal to the “principal portion” and delivery of the “share amount” in excess of the conversion value over the principal portion in shares of common stock. In general, for each $1,000 in principal, the “principal portion” of cash upon settlement is defined as the lesser of $1,000 and the conversion value during the 20-day observation period. The conversion value is the sum of the daily conversion value which is the product of the effective conversion rate divided by 20 days and the daily volume weighted average price (VWAP) of our common stock. The “share amount” is the cumulative “daily share amount” during the observation period, which is calculated by dividing the daily VWAP into the difference between the daily conversion value (i.e., conversion rate x daily VWAP) and $1,000.

The 2019 and 2021 Notes are accounted for in accordance with authoritative guidance for convertible debt instruments that may be settled in cash upon conversion. The guidance requires the carrying amount of the liability component to be estimated by estimating the fair value of a similar liability that does not have an associated conversion feature. Because we have no outstanding non-convertible public debt, we determined that market-traded senior, unsecured corporate bonds represent a similar liability without the conversion option. Based on market data available for publicly traded, senior, unsecured corporate bonds issued by companies in the same industry as us, and with similar maturities to the 2019 and 2021 Notes, we estimated the implied interest rates of our 2019 and 2021 Notes to be 2.9% and 3.5%, respectively, assuming no conversion option. Assumptions used in the estimate represent what market participants would use in pricing the liability component, including market interest rates, credit standing, and yield curves, all of which are defined as Level 2 observable inputs. The estimated implied interest rates were applied to the 2019 and 2021 Notes, which resulted in a fair value of the liability component in aggregate of $972 million upon issuance, calculated as the present value of implied future payments based on the $1,150 million aggregate principal amount. The $161 million difference between the cash proceeds of $1,133 million and the estimated fair value of the liability component was recorded in additional paid-in capital as the 2019 and 2021 Notes are not considered redeemable.

As a policy election under applicable guidance related to the calculation of diluted net income per share, we elected the combination settlement method as our stated settlement policy and apply the treasury stock method in the calculation of the potential dilutive impact of the 2019 and 2021 Notes. During the year ended December 30, 2018, the market price of our common stock met the stock trading price conversion requirement and the 2019 and 2021 Notes became convertible on October 1, 2018 and continued to be convertible through December 31, 2018. However, effective January 1, 2019, these convertible senior notes were no longer convertible. The potential dilutive impact of the 2019 and 2021 notes has been included in our calculation of diluted earnings per share for the year ended December 30, 2018. If the 2019 and 2021 Notes were converted as of December 30, 2018, their if-converted values would exceed their principal amounts by $150 million and $122 million, respectively. The carrying values of the 2019 and 2021 Notes were classified as current liabilities as they were convertible within twelve months of the balance sheet date.

Leases

We lease office and manufacturing facilities under various non-cancellable lease agreements. Facility leases generally provide for periodic rent increases, and many contain escalation clauses and renewal options. Certain leases require us to pay property taxes and routine maintenance. When we are involved in the construction of leased assets, we evaluate whether we are the accounting owner of leased assets during the construction period. As of December 31, 2017, we were considered the owner of two construction projects for accounting purposes only under build-to-suit lease accounting due to certain indemnification obligations related to the construction. During the year ended December 30, 2018, construction of these build-to-suit properties was completed. We concluded we do not qualify for sale-leaseback treatment and the leases are accounted for as financing obligations. Accordingly, $165 million of construction in progress and build-to-suit lease liability were reclassified to building asset and obligations under financing leases during the year ended December 30, 2018.

On February 28, 2017, GRAIL was deconsolidated, as further described in note “2. Balance Sheet Account Details,” and $58 million of construction in progress and the corresponding build-to-suit lease liability were removed.

As of December 30, 2018, annual future minimum payments of our operating leases and build-to-suit leases, which include those leases accounted for as a financing obligation, were as follows (in millions):
 
Operating
Leases
 
Sublease
Income
 
Net Operating
Leases
 
Build-to-suit Leases
2019
$
59

 
$
(11
)
 
$
48

 
$
18

2020
64

 
(11
)
 
53

 
21

2021
61

 
(11
)
 
50

 
21

2022
61

 
(12
)
 
49

 
22

2023
61

 
(11
)
 
50

 
22

Thereafter
439

 
(12
)
 
427

 
179

Total minimum lease payments
$
745

 
$
(68
)
 
$
677

 
$
283



Rent expense was $55 million, $46 million, and $46 million for the years ended December 30, 2018, December 31, 2017, and January 1, 2017, respectively. During the year ended December 30, 2018, the interest portion of lease expense for our build-to-suit arrangements was $13 million. As of December 30, 2018 and December 31, 2017, the deferred rent balance related to our operating leases was $123 million and $115 million, respectively, of which the long-term portion of $119 million and $113 million, respectively, was recorded in other long-term liabilities.

Purchase Obligations

In the normal course of business, we enter into agreements to purchase goods or services that are not cancelable without penalty, primarily related to licensing and supply arrangements. For those agreements with variable terms, we do not estimate the total obligation beyond any minimum quantities or pricing as of the reporting date. Licensing agreements under which we commit to minimum royalty payments, some of which are subject to adjustment, may be terminated prior to the expiration of underlying intellectual property under certain circumstances. Annual minimum payments for noncancelable purchase obligations as of December 30, 2018 were as follows (in millions):
 
Minimum Payments
2019
$
93

2020
20

Total
$
113
v3.10.0.1
Stockholders' Equity
 12 Months Ended
Dec. 30, 2018
Equity [Abstract]  
Stockholders' Equity
Stockholders’ Equity

The 2015 Stock and Incentive Compensation Plan (the 2015 Stock Plan) and the New Hire Stock and Incentive Plan allow for the issuance of stock options, restricted stock units and awards, and performance stock units. As of December 30, 2018, approximately 4.7 million shares remained available for future grants under the 2015 Stock Plan. There is no set number of shares reserved for issuance under the New Hire Stock and Incentive Plan.

Restricted Stock

We issue restricted stock units (RSU) and performance stock units (PSU), both of which are considered restricted stock. We grant restricted stock pursuant to the 2015 Stock Plan and satisfy such grants through the issuance of new shares. RSU are share awards that, upon vesting, will deliver to the holder shares of our common stock. RSU generally vest over a four-year period with equal vesting on anniversaries of the grant date. We issue PSU for which the number of shares issuable at the end of a three-year performance period can reach up to 150% of the shares approved in the award based on our performance relative to specified earnings per share targets and continued employment through the vesting period.

Restricted stock activity from January 3, 2016 through December 30, 2018 was as follows (units in thousands):
 
Restricted
Stock Units
(RSU)
 
Performance
Stock Units
(PSU)(1)
 
Weighted-Average Grant-
Date Fair Value per Share
 
 
 
RSU
 
PSU
Outstanding at January 3, 2016
2,206

 
583

 
$
131.80

 
$
169.41

Awarded
1,245

 
172

 
$
132.47

 
$
113.56

Vested
(928
)
 
(199
)
 
$
105.49

 
$
148.99

Cancelled
(230
)
 
(96
)
 
$
139.74

 
$
163.05

Outstanding at January 1, 2017
2,293

 
460

 
$
141.80

 
$
158.66

Awarded
879

 
238

 
$
207.38

 
$
191.53

Vested
(861
)
 
(92
)
 
$
131.62

 
$
189.09

Cancelled
(226
)
 
(64
)
 
$
149.03

 
$
173.83

Outstanding at December 31, 2017
2,085

 
542

 
$
172.92

 
$
166.15

Awarded
655

 
336

 
$
322.04

 
$
232.08

Vested
(731
)
 
(188
)
 
$
170.50

 
$
176.15

Cancelled
(169
)
 
(30
)
 
$
172.30

 
$
162.54

Outstanding at December 30, 2018
1,840

 
660

 
$
227.00

 
$
196.99

______________________________________
(1)
The number of units reflect the estimated number of shares to be issued at the end of the performance period.

Pre-tax intrinsic values and fair value of vested restricted stock was as follows (in millions):
 
Years Ended
 
December 30,
2018
 
December 31,
2017
 
January 1,
2017
Pre-tax intrinsic value of outstanding restricted stock:
 
 
 
 
 
RSU
$
549

 
$
456

 
$
294

PSU
$
197

 
$
118

 
$
59

 
 
 
 
 
 
Fair value of restricted stock vested:
 
 
 
 
 
RSU
$
125

 
$
113

 
$
98

PSU
$
33

 
$
17

 
$
30



Stock Options

Stock option activity from January 3, 2016 through December 30, 2018 was as follows:
 
Options
(in thousands)
 
Weighted-
Average
Exercise Price
Outstanding at January 3, 2016
1,599

 
$
41.95

Exercised
(552
)
 
$
29.41

Cancelled
(2
)
 
$
46.35

Outstanding at January 1, 2017
1,045

 
$
48.56

Exercised
(723
)
 
$
49.31

Outstanding at December 31, 2017
322

 
$
46.93

Exercised
(130
)
 
$
35.68

Outstanding and exercisable at December 30, 2018
192

 
$
54.52



The weighted-average remaining life of options outstanding and exercisable was 2.4 years as of December 30, 2018.

The aggregate intrinsic value of options outstanding and options exercisable as of December 30, 2018 was $47 million. Aggregate intrinsic value represents the product of the number of options outstanding multiplied by the difference between our closing stock price per share on the last trading day of the fiscal period, which was $298.23 as of December 28, 2018, and the exercise price. Total intrinsic value of options exercised was $33 million, $101 million, and $71 million for the years ended December 30, 2018, December 31, 2017, and January 1, 2017, respectively.

Employee Stock Purchase Plan

A total of 15.5 million shares of our common stock have been reserved for issuance under our 2000 Employee Stock Purchase Plan, or ESPP. The ESPP permits eligible employees to purchase common stock at a discount through payroll deductions during defined offering periods. The price at which stock is purchased under the ESPP is equal to 85% of the fair market value of the common stock on the first of the offering period or purchase date, whichever is lower. The initial offering period commenced in July 2000.

Approximately 0.3 million, 0.3 million, and 0.2 million shares were issued under the ESPP during the years ended December 30, 2018, December 31, 2017, and January 1, 2017, respectively. As of December 30, 2018 and December 31, 2017, there were approximately 13.7 million and 14.0 million shares available for issuance under the ESPP, respectively.

Share Repurchases

On July 28, 2016, our Board of Directors authorized a new share repurchase program, which superseded all prior and available repurchase authorizations, to repurchase $250 million of outstanding common stock. During Q1 2017, we repurchased the remaining shares, completing the program.

On May 4, 2017, our Board of Directors authorized an additional share repurchase program to repurchase $250 million of outstanding common stock. On May 1, 2018, our Board of Directors authorized an additional share repurchase program to repurchase $150 million of outstanding common stock. The repurchases may be completed under a 10b5-1 plan or at management’s discretion.

During the years ended December 30, 2018, December 31, 2017, and January 1, 2017, we repurchased approximately 0.6 million shares for $201 million (of which 0.3 million shares for $103 million was repurchased concurrently with the offering of our 2023 Notes), 1.4 million shares for $251 million, and 1.8 million shares for $249 million, respectively. Authorizations to repurchase $49 million of our common stock remained available as of December 30, 2018. On February 6, 2019, our Board of Directors authorized a new share repurchase program, which supersedes all prior and available repurchase authorizations, to repurchase $550 million of outstanding common stock. The repurchases may be completed under a 10b5-1 plan or at management’s discretion.

Share-based Compensation
    
Share-based compensation expense reported in our consolidated statements of income was as follows (in millions):
 
Years Ended
 
December 30,
2018
 
December 31,
2017
 
January 1,
2017
Cost of product revenue
$
16

 
$
12

 
$
9

Cost of service and other revenue
3

 
2

 
2

Research and development
60

 
51

 
42

Selling, general and administrative
114

 
99

 
76

Share-based compensation expense, before taxes
193

 
164

 
129

Related income tax benefits
(39
)
 
(48
)
 
(41
)
Share-based compensation expense, net of taxes
$
154

 
$
116

 
$
88


The assumptions used for the specified reporting periods and the resulting estimates of weighted-average fair value per share for stock purchased under the ESPP were as follows:
 
Years Ended
 
December 30,
2018
 
December 31,
2017
 
January 1,
2017
Risk-free interest rate
1.22% - 2.45%

 
0.50% - 1.22%

 
0.40% - 0.50%

Expected volatility
29% - 39%

 
29% - 44%

 
40% - 44%

Expected term
0.5 - 1.0 year

 
0.5 - 1.0 year

 
0.5 - 1.0 year

Expected dividends
0
%
 
0
%
 
0
%
Weighted-average grant-date fair value per share
$
61.59

 
$
46.81

 
$
48.29



As of December 30, 2018, approximately $474 million of total unrecognized compensation cost related to restricted stock and ESPP shares issued to date was expected to be recognized over a weighted-average period of approximately 2.5 years.
v3.10.0.1
Legal Proceedings
 12 Months Ended
Dec. 30, 2018
Commitments and Contingencies Disclosure [Abstract]  
Legal Proceedings
Legal Proceedings

We are involved in various lawsuits and claims arising in the ordinary course of business, including actions with respect to intellectual property, employment, and contractual matters. In connection with these matters, we assess, on a regular basis, the probability and range of possible loss based on the developments in these matters. A liability is recorded in the consolidated financial statements if it is believed to be probable that a loss has been incurred and the amount of the loss can be reasonably estimated. Because litigation is inherently unpredictable and unfavorable resolutions could occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review outstanding legal matters to determine the adequacy of the liabilities accrued and related disclosures in consideration of many factors, which include, but are not limited to, past history, scientific and other evidence, and the specifics and status of each matter. We may change our estimates if our assessment of the various factors changes and the amount of ultimate loss may differ from our estimates, resulting in a material effect on our business, financial condition, results of operations, and/or cash flows.
v3.10.0.1
Income Taxes
 12 Months Ended
Dec. 30, 2018
Income Tax Disclosure [Abstract]  
Income Taxes
Income Taxes

Income before income taxes summarized by region was as follows (in millions):
 
Years Ended
 
December 30,
2018
 
December 31,
2017
 
January 1,
2017
United States
$
54

 
$
458

 
$
120

Foreign
840

 
585

 
441

Total income before income taxes
$
894

 
$
1,043

 
$
561



The provision for income taxes consisted of the following (in millions):
 
Years Ended
 
December 30,
2018
 
December 31,
2017
 
January 1,
2017
Current:
 

 
 

 
 

Federal
$
47

 
$
259

 
$
71

State
15

 
21

 
10

Foreign
68

 
51

 
45

Total current provision
130

 
331

 
126

Deferred:
 

 
 

 
 

Federal
—

 
36

 
16

State
(16
)
 
—

 
(5
)
Foreign
(2
)
 
(2
)
 
(4
)
Total deferred (benefit) expense
(18
)
 
34

 
7

Total tax provision
$
112

 
$
365

 
$
133



The provision for income taxes reconciles to the amount computed by applying the federal statutory rate to income before taxes as follows (in millions):
 
Years Ended
 
December 30,
2018
 
December 31,
2017
 
January 1,
2017
Tax at federal statutory rate
$
188

 
$
365

 
$
196

State, net of federal benefit
13

 
19

 
10

Research and other credits
(23
)
 
(12
)
 
(13
)
Change in valuation allowance
(12
)
 
12

 
5

Impact of foreign operations
(59
)
 
(130
)
 
(86
)
Cost sharing adjustment
—

 
—

 
(7
)
Investments in consolidated variable interest entities
9

 
(3
)
 
25

Impact of U.S. Tax Reform
11

 
150

 
—

Stock compensation
(24
)
 
(41
)
 
3

Other
9

 
5

 
—

Total tax provision
$
112

 
$
365

 
$
133



In accordance with the Tax Cuts and Jobs Act that was enacted on December 22, 2017 (U.S. Tax Reform), we recorded a provision for income taxes of $150 million, which we increased by $11 million in 2018, upon completion of our 2017 tax returns. The impact of U.S. Tax Reform primarily represented our estimate of the one-time transition tax on earnings of certain foreign subsidiaries, of which $108 million is included in other long-term liabilities as of December 30, 2018; and the impact of revaluing our U.S. deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future. For U.S. federal purposes the corporate statutory income tax rate was reduced from 35% to 21%, effective for our 2018 tax year. Although the Company no longer considers these items to be provisional, under Staff Accounting Bulletin 118, the determination of the U.S. Tax Reform’s income tax effects may change following future legislation or further interpretation of the U.S. Tax Reform based on the publication of recently proposed U.S. Treasury regulations and guidance from the Internal Revenue Service and state tax authorities. We continue to evaluate the impacts of U.S. Tax Reform as we interpret the legislation, including the newly enacted global intangible low-taxed income (GILTI) provisions which subject our foreign earnings to a minimum level of tax.  We have elected to account for GILTI as a period cost in our consolidated financial statements.

The impact of foreign operations primarily represents the difference between the actual provision for income taxes for our legal entities that operate primarily in jurisdictions that have statutory tax rates lower than the U.S. federal statutory tax rate of 21%. The most significant tax benefits from foreign operations were from our earnings in Singapore and the United Kingdom, which had statutory tax rates of 17% and 19%, respectively, in the year ended December 30, 2018. The impact of foreign operations also includes the U.S. foreign tax credit impact of non-U.S. earnings and uncertain tax positions related to foreign items.

Significant components of deferred tax assets and liabilities were as follows (in millions):
 
December 30,
2018
 
December 31,
2017
Deferred tax assets:
 

 
 

Net operating losses
$
26

 
$
18

Tax credits
63

 
57

Other accruals and reserves
28

 
25

Stock compensation
20

 
19

Deferred rent
30

 
28

Cost sharing adjustment
21

 
21

Other amortization
13

 
12

Lease obligation
70

 
27

Investments
1

 
13

Other
28

 
26

Total gross deferred tax assets
300

 
246

Valuation allowance on deferred tax assets
(15
)
 
(25
)
Total deferred tax assets
285

 
221

Deferred tax liabilities:
 

 
 

Purchased intangible amortization
(32
)
 
(26
)
Convertible debt
(41
)
 
(18
)
Property and equipment
(94
)
 
(44
)
Investments
(45
)
 
(40
)
Other
(3
)
 
(5
)
Total deferred tax liabilities
(215
)
 
(133
)
Deferred tax assets, net
$
70

 
$
88



A valuation allowance is established when it is more likely than not the future realization of all or some of the deferred tax assets will not be achieved. The evaluation of the need for a valuation allowance is performed on a jurisdiction-by-jurisdiction basis and includes a review of all available positive and negative evidence. Based on the available evidence as of December 30, 2018, we were not able to conclude it is more likely than not certain deferred tax assets will be realized. Therefore, a valuation allowance of $15 million was recorded against certain U.S. and foreign deferred tax assets.

As of December 30, 2018, we had net operating loss carryforwards for federal and state tax purposes of $39 million and $156 million, respectively, which will begin to expire in 2019, unless utilized prior. We also had federal and state tax credit carryforwards of $1 million and $103 million, which will begin to expire in 2037 and 2022, respectively, unless utilized prior.

Pursuant to Section 382 and 383 of the Internal Revenue Code, utilization of net operating losses and credits may be subject to annual limitations in the event of any significant future changes in its ownership structure. These annual limitations may result in the expiration of net operating losses and credits prior to utilization. The deferred tax assets as of December 30, 2018 are net of any previous limitations due to Section 382 and 383.

Our manufacturing operations in Singapore operate under various tax holidays and incentives that begin to expire in 2023. These tax holidays and incentives resulted in a $36 million, $49 million, and $32 million decrease to the provision for income taxes for the years ended December 30, 2018, December 31, 2017, and January 1, 2017, respectively. These tax holidays and incentives resulted in an increase in diluted earnings per share attributable to Illumina stockholders of $0.24, $0.33, and $0.22, for the years ended December 30, 2018, December 31, 2017, and January 1, 2017, respectively.

It is our intention to indefinitely reinvest the historical earnings of our foreign subsidiaries generated prior to 2017 to ensure sufficient working capital and to expand existing operations outside the United States. Accordingly, state and foreign income and withholding taxes have not been provided on $973 million of undistributed earnings of foreign subsidiaries as of December 30, 2018. In the event we are required to repatriate funds from outside of the United States, such repatriation would be subject to local laws, customs, and tax consequences. As of December 30, 2018, we asserted that $63 million of foreign earnings would not be indefinitely reinvested, and accordingly, recorded a deferred tax liability of $2 million.

The following table summarizes the gross amount of our uncertain tax positions (in millions):
 
December 30,
2018
 
December 31,
2017
 
January 1,
2017
Balance at beginning of year
$
79

 
$
65

 
$
56

Increases related to prior year tax positions
1

 
2

 
—

Decreases related to prior year tax positions
(1
)
 
—

 
(2
)
Increases related to current year tax positions
12

 
14

 
13

Decreases related to lapse of statute of limitations
(3
)
 
(2
)
 
(2
)
Balance at end of year
$
88

 
$
79

 
$
65



Included in the balance of uncertain tax positions as of December 30, 2018 and December 31, 2017, were $78 million and $70 million, respectively, of net unrecognized tax benefits that, if recognized, would reduce the effective income tax rate in future periods.

Any interest and penalties related to uncertain tax positions are reflected in the provision for income taxes. We recognized expense of $3 million, $1 million, and $1 million during the years ended December 30, 2018, December 31, 2017, and January 1, 2017, respectively, related to potential interest and penalties on uncertain tax positions. We recorded a liability for potential interest and penalties of $11 million and $8 million as of December 30, 2018 and December 31, 2017, respectively.

Tax years 1997 to 2017 remain subject to future examination by the major tax jurisdictions in which we are subject to tax. Given the uncertainty of potential adjustments from examination as well as the potential expiration of the statute of limitations, it is reasonably possible that the balance of unrecognized tax benefits could change significantly over the next 12 months. Due to the number of years remaining that are subject to examination, we are unable to estimate the full range of possible adjustments to the balance of gross unrecognized tax benefits.
v3.10.0.1
Employee Benefit Plans
 12 Months Ended
Dec. 30, 2018
Deferred Compensation Arrangements [Abstract]  
Employee Benefit Plans
Employee Benefit Plans

Retirement Plan

We have a 401(k) savings plan covering substantially all of our employees in the United States. Our contributions to the plan are discretionary. During the years ended December 30, 2018, December 31, 2017, and January 1, 2017, we made matching contributions of $20 million, $17 million, and $14 million, respectively.

Deferred Compensation Plan

The Illumina, Inc. Deferred Compensation Plan (the Plan) allows senior level employees to contribute up to 60% of their base salary and 100% of their variable cash compensation, and members of the board of directors to contribute up to 100% of their director fees and equity awards. Under the Plan, we credit the participants’ contributions with earnings that reflect the performance of certain independent investment funds. On a discretionary basis, we may also make employer contributions to participant accounts in any amount determined by us. The vesting schedules of employer contributions are at the sole discretion of the Compensation Committee. However, all employer contributions shall become 100% vested upon the occurrence of the participant’s disability, death or retirement or a change in control of Illumina. The benefits under this plan are unsecured. Participants are generally eligible to receive payment of their vested benefit at the end of their elected deferral period or after termination of their employment for any reason or at a later date to comply with the restrictions of Section 409A.

We also established a rabbi trust for the benefit of the participants under the Plan and have included the assets of the rabbi trust in the consolidated balance sheets. As of December 30, 2018 and December 31, 2017, the assets of the trust were $34 million and $35 million, respectively, and our liabilities were $33 million in both years. The assets and liabilities are classified as other assets and accrued liabilities, respectively, on the consolidated balance sheets. Changes in the values of the assets held by the rabbi trust are recorded in other income (expense), net in the consolidated statements of income, and changes in the values of the deferred compensation liabilities are recorded in cost of revenue or operating expenses.
v3.10.0.1
Segment Information and Geographic Data
 12 Months Ended
Dec. 30, 2018
Segment Reporting [Abstract]  
Segment Information and Geographic Data
Segment Information and Geographic Data

We have two reportable segments: Core Illumina and one segment related to the combined activities of our Consolidated VIEs. Our Consolidated VIEs currently include only the operations of Helix, whereas prior to the deconsolidation of GRAIL on February 28, 2017, our Consolidated VIEs included the combined operations of Helix and GRAIL.

We report segment information based on the management approach. This approach designates the internal reporting used by the Chief Operating Decision Maker (CODM) for making decisions and assessing performance as the source of our reportable segments. The CODM allocates resources and assesses the performance of each operating segment using information about its revenue and income (loss) from operations. Based on the information used by the CODM, we have determined our reportable segments as follows:

Core Illumina:

Core Illumina’s products and services serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Core Illumina includes all of our operations, excluding the results of our consolidated VIEs.

Consolidated VIEs:

Helix: Helix was established to enable individuals to explore their genetic information by providing affordable sequencing and database services for consumers through third-party partners, driving the creation of an ecosystem of consumer applications.

GRAIL: GRAIL was created to develop a blood test for early-stage cancer detection. GRAIL was in the early stages of developing this test and as such, had no revenues through the date of deconsolidation.

Management evaluates the performance of our reportable segments based upon income (loss) from operations. We do not allocate expenses between segments. Core Illumina sells products and provides services to Helix and GRAIL in accordance with contractual agreements between the entities.

The following table presents the operating performance of each reportable segment (in millions):
 
Years Ended
 
December 30,
2018
 
December 31,
2017
 
January 1,
2017
Revenue:
 
 
 
 
 
Core Illumina
$
3,334

 
$
2,754

 
$
2,428

Consolidated VIEs
10

 
6

 
—

Eliminations
(11
)
 
(8
)
 
(30
)
Consolidated revenue
$
3,333

 
$
2,752

 
$
2,398

 
 
 
 
 
 
Depreciation and amortization:
 
 
 
 
 
Core Illumina
$
175

 
$
153

 
$
138

Consolidated VIEs
6

 
6

 
4

Eliminations
(2
)
 
(3
)
 
(1
)
Consolidated depreciation and amortization
$
179

 
$
156

 
$
141

 
 
 
 
 
 
Income (loss) from operations:
 
 
 
 
 
Core Illumina
$
970

 
$
696

 
$
684

Consolidated VIEs
(90
)
 
(92
)
 
(81
)
Eliminations
3

 
2

 
(16
)
Consolidated income from operations
$
883

 
$
606

 
$
587


Other income (expense), net primarily relates to Core Illumina and we do not allocate income taxes to our segments.

The following table presents the total assets and capital expenditures of each reportable segment (in millions):
 
Years Ended
 
December 30,
2018
 
December 31,
2017
 
January 1,
2017
Total assets:
 
 
 
 
 
Core Illumina
$
6,912

 
$
5,223

 
$
4,167

Consolidated VIEs
154

 
45

 
180

Eliminations
(107
)
 
(11
)
 
(66
)
Consolidated total assets
$
6,959

 
$
5,257

 
$
4,281

 
 
 
 
 
 
Capital expenditures:
 
 
 
 
 
Core Illumina
$
294

 
$
306

 
$
238

Consolidated VIEs
2

 
4

 
22

Consolidated capital expenditures
$
296

 
$
310

 
$
260



Net long-lived assets exclude goodwill and other intangible assets since they are not allocated on a geographic basis. We had net long-lived assets, consisting of property and equipment, in the following regions as of December 30, 2018 and December 31, 2017 (in millions):
 
December 30,
2018
 
December 31,
2017
United States
$
907

 
$
828

Singapore
96

 
54

United Kingdom
62

 
43

Other countries
10

 
6

Total
$
1,075

 
$
931

Refer to note “1. Organization and Summary of Significant Accounting Policies” for revenue by geographic area.
v3.10.0.1
Quarterly Financial Information (unaudited)
 12 Months Ended
Dec. 30, 2018
Quarterly Financial Information Disclosure [Abstract]  
Quarterly Financial Information (unaudited)
Quarterly Financial Information (unaudited)

The following financial information reflects all normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the results and cash flows of interim periods. All quarters for fiscal years 2018 and 2017, ended December 30, 2018 and December 31, 2017, respectively, were 13 weeks. Summarized quarterly data for fiscal years 2018 and 2017 are as follows (in millions, except per share amounts):
 
First Quarter
 
Second Quarter
 
Third Quarter
 
Fourth Quarter
2018
 

 
 

 
 

 
 

Total revenue
$
782

 
$
830

 
$
853

 
$
867

Gross profit
$
538

 
$
575

 
$
597

 
$
590

Consolidated net income
$
197

 
$
200

 
$
188

 
$
198

Net income attributable to Illumina stockholders
$
208

 
$
209

 
$
199

 
$
210

Earnings per share attributable to Illumina stockholders:
 
 
 
 
 
 
 
Basic
$
1.42

 
$
1.42

 
$
1.35

 
$
1.43

Diluted
$
1.41

 
$
1.41

 
$
1.33

 
$
1.41

2017
 
 
 
 
 
 
 
Total revenue
$
598

 
$
662

 
$
714

 
$
778

Gross profit
$
368

 
$
434

 
$
482

 
$
542

Consolidated net income
$
348

 
$
120

 
$
152

 
$
58

Net income attributable to Illumina stockholders (a)
$
367

 
$
128

 
$
163

 
$
68

Earnings per share attributable to Illumina stockholders:
 
 
 
 
 
 
 
Basic
$
2.50

 
$
0.87

 
$
1.12

 
$
0.47

Diluted
$
2.48

 
$
0.87

 
$
1.11

 
$
0.46


Certain amounts may not recalculate using the rounded amounts provided.

(a) First quarter of 2017 includes the results of GRAIL through February 28, 2017, the date of deconsolidation. Refer to note “2. Balance Sheet Account Details” for further discussion.
v3.10.0.1
Organization and Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 30, 2018
Accounting Policies [Abstract]  
Basis of Presentation
The consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles and include our accounts, our wholly-owned subsidiaries, majority-owned or controlled companies, and variable interest entities (VIEs) for which we are the primary beneficiary. All intercompany transactions and balances have been eliminated in consolidation.
Variable Interest Entities
We evaluate our ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether we are the primary beneficiary of the VIE. In determining whether we are the primary beneficiary of a VIE and therefore required to consolidate the VIE, we apply a qualitative approach that determines whether we have both (1) the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. We continuously assess whether we are the primary beneficiary of a VIE, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of such VIE. During the year ended December 30, 2018, our consolidated VIE, Helix, received additional cash contributions from us and third-party investors in exchange for voting equity interests in Helix. Therefore, we reassessed and concluded that Helix continued to be a variable interest entity and that we remained the primary beneficiary. During the periods presented, we have not provided any other financial or other support to our VIEs that we were not contractually required to provide.
Equity Method Investments
The equity method is used to account for investments over which we have the ability to exercise significant influence, but not control, over the investee. Such investments are recorded within other assets, and the share of net income or losses of equity investments is recognized on a one quarter lag in other income (expense), net.
Redeemable Noncontrolling Interests
Noncontrolling interests represent the portion of equity (net assets) in Helix, our consolidated but not wholly-owned entity, that is neither directly nor indirectly attributable to us. Noncontrolling interests with embedded contingent redemption features, such as put rights, that are not solely within our control are considered redeemable noncontrolling interests. Redeemable noncontrolling interests are presented outside of stockholders’ equity on the consolidated balance sheets.
Fiscal Year
Our fiscal year is the 52 or 53 weeks ending the Sunday closest to December 31, with quarters of 13 or 14 weeks ending the Sunday closest to March 31, June 30, September 30, and December 31. The years ended December 30, 2018, December 31, 2017, and January 1, 2017 were all 52 weeks.

Reclassifications
Certain prior period amounts have been reclassified to conform to the current period presentation.
Use of Estimates
The preparation of the consolidated financial statements requires that management make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures of contingent assets and liabilities. Actual results could differ from those estimates.
Recently Adopted and Issued Accounting Pronouncements
Accounting Pronouncements Adopted in 2018

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). The new standard is based on the principle that revenue should be recognized in an amount that reflects the consideration to which we expect to be entitled in exchange for the transfer of promised goods or services. We adopted Topic 606 using the modified retrospective transition method. The cumulative effect of applying the new revenue standard to all incomplete contracts as of January 1, 2018 was not material and, therefore, did not result in an adjustment to retained earnings. There was no material difference to the consolidated financial statements for the year ended December 30, 2018 due to the adoption of Topic 606.

In January 2016, the FASB issued ASU 2016-01, Financial Instruments - Overall (Subtopic 825-10), which requires equity investments (other than those accounted for under the equity method or those that result in consolidation) to be measured at fair value, with changes in fair value recognized in net income. This standard was effective for us beginning in the first quarter of 2018. Based on our elections, our equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer. This measurement alternative was applied prospectively to such equity securities and did not result in an adjustment to retained earnings.

Accounting Pronouncements Adopted in 2017

In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718), which aims to simplify the accounting for share-based payment transactions, including accounting for income taxes, classification on the statement of cash flows, accounting for forfeitures, and classification of awards as either liabilities or equity. This ASU was effective for us beginning in the first quarter of 2017.

This new standard increases the volatility of net income by requiring excess tax benefits from share-based payment arrangements to be classified as discrete items within the provision for income taxes, rather than recognizing excess tax benefits in additional paid-in capital. Upon adoption in Q1 2017, we recorded $45 million, net, to retained earnings, primarily related to unrealized tax benefits associated with share-based compensation. As a result of the adoption of this new standard, we made an accounting policy election to recognize forfeitures as they occur and no longer estimate expected forfeitures.

In addition, ASU 2016-09 requires that excess income tax benefits from share-based compensation arrangements be classified as cash flow from operations, rather than cash flow from financing activities. We elected to apply the cash flow classification guidance retrospectively and reclassified $91 million from financing activity to operating activity for the year ended January 1, 2017.

Recently Issued Accounting Pronouncements

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842).  The new standard requires lessees to recognize most leases on their balance sheet as lease liabilities with corresponding right-of-use assets and disclose key information about leasing arrangements.  ASU 2016-02 is effective for us beginning in the first quarter of 2019 and will be adopted using a modified retrospective approach by recognizing a cumulative-effect adjustment to the opening balance of retained earnings on December 31, 2018. We will continue to report financial information for fiscal years ending before December 31, 2018 under the current lease accounting standard. 

We elected the standard’s package of practical expedients on adoption, which allows us to carry forward our historical assessment of whether existing agreements contain a lease and the classification of our existing lease agreements as either operating or capital leases (referred to as operating and financing leases in the new standard).  We did not elect the standard’s available hindsight practical expedient on adoption.  The standard also provides practical expedients for ongoing lessee accounting after adoption. We expect to elect the practical expedient to not separate lease and non-lease components for our real-estate leases and will therefore allocate all fixed lease payments, which may include management fees and common-area-maintenance charges, to our operating lease liabilities and corresponding right-of-use assets. 

We have finalized the changes to our systems, processes, policies, and controls for lease accounting, including implementation of a third-party software application, to facilitate our adoption of the lease standard effective December 31, 2018.  We expect the most significant impacts of adoption to result from the recognition of our operating and build-to-suit lease commitments as lease liabilities with corresponding right-of-use assets, and the derecognition of existing assets and liabilities for our build-to-suit arrangements that do not qualify for sale-leaseback accounting.  We currently expect this will result in the net recognition of additional total assets and liabilities of approximately $329 million and $354 million, respectively, and the difference between these amounts will be recorded as a cumulative-effect adjustment to retained earnings upon adoption in the first quarter of 2019.  We also expect the classification of a portion of lease expense for our build-to-suit arrangements to change from interest expense to operating expense going forward.  During the year ended December 30, 2018, the interest portion of lease expense for our build-to-suit arrangements was $13 million.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available-for-sale debt securities. The standard is effective for us beginning in the first quarter of 2020, with early adoption permitted.  We are currently evaluating the expected impact of ASU 2016-13 on our consolidated financial statements.
Concentrations of Risk
International sales entail a variety of risks, including currency exchange fluctuations, longer payment cycles, and greater difficulty in accounts receivable collection. We are also subject to general geopolitical risks, such as political, social and economic instability, and changes in diplomatic and trade relations. The risks of international sales are mitigated in part by the extent to which sales are geographically distributed.

Historically, we have not experienced significant credit losses from investments and accounts receivable.
We operate in markets that are highly competitive and rapidly changing. Significant technological changes, shifting customer needs, the emergence of competitive products or services with new capabilities, and other factors could negatively impact our operating results. A portion of our customers consist of university and research institutions that management believes are, to some degree, directly or indirectly supported by the United States Government. A significant change in current research funding, particularly with respect to the U.S. National Institutes of Health, could have an adverse impact on future revenues and results of operations.

We are also subject to risks related to our financial instruments, including cash and cash equivalents, investments, and accounts receivable. Most of our cash and cash equivalents as of December 30, 2018 were deposited with U.S. financial institutions, either domestically or with their foreign branches. Our investment policy restricts the amount of credit exposure to any one issuer to 5% of the portfolio or 5% of the total issue size outstanding at the time of purchase and to any one industry sector, as defined by Clearwater Analytics (Industry Sector Report), to 30% of the portfolio at the time of purchase. There is no limit to the percentage of the portfolio that may be maintained in debt securities, U.S. government-sponsored entities, U.S. Treasury securities, and money market funds.

We require customized products and components that currently are available from a limited number of sources. We source certain key products and components included in our products from single vendors.

We perform regular reviews of customer activity and associated credit risks and do not require collateral or enter into netting arrangements.
Fair Value Measurements
The fair value of assets and liabilities are based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. We use a fair value hierarchy with three levels of inputs, of which the first two are considered observable and the last unobservable, to measure fair value:

•
Level 1 — Quoted prices in active markets for identical assets or liabilities.
•
Level 2 — Inputs, other than Level 1, that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
•
Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The carrying amounts of financial instruments such as cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable, and accrued liabilities approximate the related fair values due to the short-term maturities of these instruments.

Functional Currency
The U.S. dollar is the functional currency of our international operations. We re-measure foreign subsidiaries’ monetary assets and liabilities to the U.S. dollar and record the net gains or losses resulting from re-measurement in other income (expense), net in the consolidated statements of income.

Acquisitions
All assets acquired and liabilities assumed are measured at fair value as of the acquisition date. We record the excess of purchase price over the aggregate value assigned to the net tangible and identifiable intangible assets acquired as goodwill. Acquired intangible assets other than goodwill are amortized over their useful lives. Post-acquisition adjustments in deferred tax asset valuation allowances and liabilities for uncertain tax positions are recorded in current period income tax expense.
Cash Equivalents
Cash equivalents are comprised of short-term, highly-liquid investments with maturities of 90 days or less at the date of purchase.
Short-Term Investments
Short-term investments consist of debt securities in U.S. government-sponsored entities, corporate debt securities, U.S. Treasury securities, and equity securities. We classify short-term debt investments as available-for-sale at the time of purchase and evaluate such classification as of each balance sheet date. All short-term debt investments are recorded at estimated fair value. Unrealized gains and losses for available-for-sale debt securities are included in accumulated other comprehensive income (loss), a component of stockholders’ equity. We evaluate our debt investments to assess whether those with unrealized loss positions are other than temporarily impaired. Impairments are considered to be other than temporary if they are related to deterioration in credit risk or if it is likely that the securities will be sold before the recovery of their cost basis. Realized gains, losses, and declines in value judged to be other than temporary are determined based on the specific identification method and are recorded in interest income (expense), net in the consolidated statements of income.

Equity investments with readily determinable fair values are classified as current or noncurrent based on the nature of the securities and their availability for use in current operations. All short-term equity investments are recorded at estimated fair value. Unrealized gains and losses for equity securities with readily determinable fair values are recorded in other income (expense), net in the consolidated statements of income.
Accounts Receivable
Trade accounts receivable are recorded at the net invoice value and are not interest-bearing. Receivables are considered past due based on the contractual payment terms. We reserve specific receivables if collectibility is no longer reasonably assured. We also reserve a percentage of our trade receivable balance based on collection history and current economic trends that might impact the level of future credit losses. These reserves are re-evaluated on a regular basis and adjusted as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the reserve.

Inventory
Inventory is stated at the lower of cost or net realizable value, on a first-in, first-out basis. Inventory includes raw materials and finished goods that may be used in the research and development process, and such items are expensed as consumed or expired. Inventory write-downs for slow-moving, excess, and obsolete inventories are estimated based on product life cycles, quality issues, historical experience, and usage forecasts.
Property and Equipment
Property and equipment are stated at cost, subject to review for impairment, and depreciated over the estimated useful lives of the assets, using the straight-line method. Depreciation of leasehold improvements is recorded over the shorter of the lease term or the estimated useful life of the related assets. Amortization of assets that are recorded under capital leases are included in depreciation expense. Maintenance and repairs are expensed as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in operating expense.

Costs incurred to develop internal-use software during the application development stage are recorded as computer software costs, at cost. Costs incurred in the development of such internal-use software, including external direct costs of materials and services and applicable compensation costs of employees devoted to specific software application development, are capitalized. Cost incurred outside of the application development stage are expensed as incurred.

The estimated useful lives of the major classes of property and equipment are generally as follows:
 
Estimated Useful Lives
Buildings and leasehold improvements
4 to 20 years
Machinery and equipment
3 to 5 years
Computer hardware and software
3 to 7 years
Furniture and fixtures
7 years
Leases
Leases are reviewed and classified as capital or operating at their inception. When we are involved in the construction of leased assets, we evaluate whether we are the accounting owner during the construction period. For leases where we are the deemed accounting owner during the construction period, we record project construction costs paid or reimbursed by the landlord as construction in progress and a corresponding build-to-suit lease liability. For operating leases, rent expense is recorded on a straight-line basis over the term of the lease, which includes the construction build-out period and lease extension periods, if appropriate. The difference between rent payments and straight-line rent expense is recorded as deferred rent in accrued liabilities and other long-term liabilities. Lease incentives are amortized on a straight-line basis over the lease term as a reduction to rent expense.
Goodwill, Intangible Assets and Other Long-Lived Assets
Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired in an acquisition. Goodwill is reviewed for impairment at least annually during the second quarter, or more frequently if an event occurs indicating the potential for impairment. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair values of our reporting units are less than the carrying amounts, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair values of our reporting units are less than the carrying amounts, then no additional assessment is deemed necessary. Otherwise, we proceed to perform the two-step test for goodwill impairment. The first step involves comparing the estimated fair values of the reporting units with the carrying values, including goodwill. If the carrying amounts of the reporting units exceed the fair values, the second step of the goodwill impairment test is performed to determine the amount of loss, which involves comparing the implied fair values of the goodwill to the carrying values of the goodwill. We may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the first step of the goodwill impairment test. We performed the annual assessment for goodwill impairment in the second quarter of 2018, noting no impairment.

Our identifiable intangible assets are typically comprised of acquired core technologies, licensed technologies, customer relationships, license agreements, and trade names. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets’ respective estimated useful lives.

We perform regular reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to the net book value, significant changes in the ability of a particular asset to generate positive cash flows for our strategic business objectives, and the pattern of utilization of a particular asset.
Derivatives
We are exposed to foreign exchange rate risks in the normal course of business. We enter into foreign exchange contracts to manage foreign currency risks related to monetary assets and liabilities that are denominated in currencies other than the U.S. dollar. These foreign exchange contracts are carried at fair value in other current assets or accrued liabilities and are not designated as hedging instruments. Changes in the value of the derivatives are recognized in other income (expense), net, along with the re-measurement gain or loss on the foreign currency denominated assets or liabilities.

Warranties
We generally provide a one-year warranty on instruments. Additionally, a warranty on consumables is provided through the expiration date, which generally ranges from six to twelve months after the manufacture date. At the time revenue is recognized, an accrual is established for estimated warranty expenses based on historical experience as well as anticipated product performance. We periodically review the warranty reserve for adequacy and adjust the warranty accrual, if necessary, based on actual experience and estimated costs to be incurred. Warranty expense is recorded as a component of cost of product revenue.
Revenue Recognition and Shipping and Handling Expenses
Shipping and handling expenses are included in cost of product revenue.
Our revenue is generated primarily from the sale of products and services. Product revenue primarily consists of sales of instruments and consumables used in genetic analysis. Service and other revenue primarily consists of revenue generated from genotyping and sequencing services and instrument service contracts.

We recognize revenue when control of our products and services is transferred to our customers in an amount that reflects the consideration we expect to receive from our customers in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. We consider a performance obligation satisfied once we have transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service.

Revenue from product sales is recognized generally upon delivery to the end customer, which is when control of the product is deemed to be transferred. Invoicing typically occurs upon shipment and payment is typically due within 60 days from invoice. In instances where right of payment or transfer of title is contingent upon the customer’s acceptance of the product, revenue is deferred until all acceptance criteria have been met. Revenue from instrument service contracts is recognized as the services are rendered, typically evenly over the contract term. Revenue from genotyping and sequencing services is recognized when earned, which is generally at the time the genotyping or sequencing analysis data is made available to the customer.

Revenue is recorded net of discounts, distributor commissions, and sales taxes collected on behalf of governmental authorities. Employee sales commissions are recorded as selling, general and administrative expenses when incurred as the amortization period for such costs, if capitalized, would have been one year or less.

We regularly enter into contracts with multiple performance obligations. Revenue recognition for contracts with multiple deliverables is based on the separate satisfaction of each distinct performance obligation within the contract.  Most performance obligations are generally satisfied within a short time frame, approximately three to six months, after the contract execution date. As of December 30, 2018, the aggregate amount of the transaction price allocated to remaining performance obligations was $909 million, of which approximately 80% is expected to be converted to revenue through 2019, with the remainder thereafter.

The contract price is allocated to each performance obligation in proportion to its standalone selling price. We determine our best estimate of standalone selling price using average selling prices over a rolling 12-month period coupled with an assessment of current market conditions. If the product or service has no history of sales or if the sales volume is not sufficient, we rely upon prices set by management, adjusted for applicable discounts.

Contract liabilities, which consist of deferred revenue and customer deposits, as of December 30, 2018 and December 31, 2017 were $206 million and $181 million, respectively, of which the short-term portions of $175 million and $150 million, respectively, were recorded in accrued liabilities and the remaining long-term portions were recorded in other long-term liabilities. Revenue recorded during the year ended December 30, 2018 included $146 million of previously deferred revenue that was included in contract liabilities as of December 31, 2017. Contract assets as of December 30, 2018 and December 31, 2017 were not material.

In certain markets, products and services are sold to customers through distributors. In most sales through distributors, the product is delivered directly to customers by us. The terms of sales transactions through distributors are consistent with the terms of direct sales to customers.
Share-Based Compensation
Share-based compensation expense is incurred related to restricted stock and Employee Stock Purchase Plan (ESPP).

Restricted stock units (RSU) and performance stock units (PSU) are both considered restricted stock. The fair value of restricted stock is determined by the closing market price of our common stock on the date of grant. Share-based compensation expense is recognized based on the fair value on a straight-line basis over the requisite service periods of the awards. PSU represents a right to receive a certain number of shares of common stock based on the achievement of corporate performance goals and continued employment during the vesting period. At each reporting period, we reassess the probability of the achievement of such corporate performance goals and any additional expenses resulting from an adjustment in the estimated shares to be released are treated as a cumulative catch-up in the period of adjustment.

The Black-Scholes-Merton option-pricing model is used to estimate the fair value of stock purchased under our ESPP. The model assumptions include expected volatility, term, dividends, and the risk-free interest rate. The expected volatility is determined by equally weighing the historical and implied volatility of our common stock. The historical volatility is generally commensurate with the estimated expected term, adjusted for the impact of unusual fluctuations and other relevant factors. The implied volatility is calculated from the implied market volatility of exchange-traded call options on our common stock. The expected term is based on historical forfeiture experience and the terms and conditions of the ESPP. The expected dividend yield is determined to be 0% given that we have never declared or paid cash dividends on our common stock and do not anticipate paying such cash dividends. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected term of the share-based awards.

Forfeitures are accounted for as incurred as reversal of any share-based compensation expense related to awards that will not vest.
Research and Development
Research and development expenses include personnel expenses, contractor fees, license fees, facilities costs, and utilities. Expenditures relating to research and development are expensed in the period incurred.
Advertising Costs
Advertising costs are expensed as incurred.
Income Taxes
The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for the expected future tax benefit to be derived from tax loss and credit carryforwards. Deferred tax assets and liabilities are determined using the enacted tax rates in effect for the years in which those tax assets are expected to be realized. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date.

Deferred tax assets are regularly assessed to determine the likelihood they will be recovered from future taxable income. A valuation allowance is established when we believe it is more likely than not the future realization of all or some of a deferred tax asset will not be achieved. In evaluating the ability to recover deferred tax assets within the jurisdiction which they arise, we consider all available positive and negative evidence. Factors reviewed include the cumulative pre-tax book income for the past three years, scheduled reversals of deferred tax liabilities, history of earnings and reliable forecasting, projections of pre-tax book income over the foreseeable future, and the impact of any feasible and prudent tax planning strategies.

The impact of a tax position is recognized in the consolidated financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected in income tax expense.

Earnings per Share
Basic earnings per share attributable to Illumina stockholders is computed based on the weighted average number of common shares outstanding during the period. Diluted earnings per share attributable to Illumina stockholders is computed based on the sum of the weighted average number of common shares and potentially dilutive common shares outstanding during the period. Per-share earnings of our VIEs are included in the consolidated basic and diluted earnings per share computations based on our share of the VIE’s securities.

Potentially dilutive common shares consist of shares issuable under convertible senior notes and equity awards. Convertible senior notes have a dilutive impact when the average market price of our common stock exceeds the applicable conversion price of the respective notes. Potentially dilutive common shares from equity awards are determined using the average share price for each period under the treasury stock method. In addition, proceeds from exercise of equity awards and the average amount of unrecognized compensation expense for equity awards are assumed to be used to repurchase shares.
v3.10.0.1
Organization and Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 30, 2018
Accounting Policies [Abstract]  
Summary of Estimated Useful Lives of Major Classes of Property and Equipment
The estimated useful lives of the major classes of property and equipment are generally as follows:
 
Estimated Useful Lives
Buildings and leasehold improvements
4 to 20 years
Machinery and equipment
3 to 5 years
Computer hardware and software
3 to 7 years
Furniture and fixtures
7 years
Property and equipment, net consisted of the following (in millions):
 
December 30,
2018
 
December 31,
2017
Leasehold improvements
$
567

 
$
331

Machinery and equipment
382

 
316

Computer hardware and software
217

 
185

Furniture and fixtures
45

 
34

Buildings
285

 
155

Construction in progress
100

 
326

Total property and equipment, gross
1,596

 
1,347

Accumulated depreciation
(521
)
 
(416
)
Total property and equipment, net
$
1,075

 
$
931
Disaggregation of Revenue
The following table represents revenue by source (in millions):
 
Years Ended
 
December 30,
2018
 
December 31,
2017
 
January 1,
2017
 
Sequencing
 
Microarray
 
Total
 
Sequencing
 
Microarray
 
Total
 
Sequencing
 
Microarray
 
Total
Consumables
$
1,806

 
$
350

 
$
2,156

 
$
1,468

 
$
285

 
$
1,753

 
$
1,271

 
$
272

 
$
1,543

Instruments
532

 
37

 
569

 
484

 
31

 
515

 
450

 
19

 
469

Other product
21

 
3

 
24

 
19

 
2

 
21

 
18

 
2

 
20

Total product revenue
2,359

 
390

 
2,749

 
1,971

 
318

 
2,289

 
1,739

 
293

 
2,032

Service and other revenue
416

 
168

 
584

 
322

 
141

 
463

 
277

 
89

 
366

Total revenue
$
2,775

 
$
558

 
$
3,333

 
$
2,293

 
$
459

 
$
2,752

 
$
2,016

 
$
382

 
$
2,398

The following table represents revenue by geographic area, based on region of destination (in millions):
 
Years Ended
 
December 30,
2018
 
December 31,
2017
 
January 1,
2017
Americas (1)
$
1,864

 
$
1,585

 
$
1,367

Europe, Middle East, and Africa
851

 
653

 
575

Greater China (2)
365

 
292

 
—

Asia-Pacific
253

 
222

 
456

Total revenue
$
3,333

 
$
2,752

 
$
2,398

____________________________________
(1) Revenue for the Americas region included United States revenue of $1,779 million, $1,511 million, and $1,294 million for the years ended December 30, 2018, December 31, 2017, and January 1, 2017, respectively.
(2) Revenue for the Greater China region, which includes China, Taiwan, and Hong Kong, is included in the Asia-Pacific region for the year ended January 1, 2017.
Summary of Calculation of Weighted Average Shares used to Calculate Basic and Diluted Earnings Per Share, Earnings Per Share
The following table presents the calculation of weighted average shares used to calculate basic and diluted earnings per share (in millions):
 
Years Ended
 
December 30,
2018
 
December 31,
2017
 
January 1,
2017
Weighted average shares outstanding
147

 
146

 
147

Effect of potentially dilutive common shares from:
 
 
 
 
 
Convertible senior notes
1

 
—

 
—

Equity awards
1

 
2

 
1

Weighted average shares used in calculating diluted earnings per share
149

 
148

 
148
Summary of Calculation of Weighted Average Shares used to Calculate Basic and Diluted Earnings Per Share, Antidilutive Securities
The following table presents the calculation of weighted average shares used to calculate basic and diluted earnings per share (in millions):
 
Years Ended
 
December 30,
2018
 
December 31,
2017
 
January 1,
2017
Weighted average shares outstanding
147

 
146

 
147

Effect of potentially dilutive common shares from:
 
 
 
 
 
Convertible senior notes
1

 
—

 
—

Equity awards
1

 
2

 
1

Weighted average shares used in calculating diluted earnings per share
149

 
148

 
148
Summary of Components of Accumulated Other Comprehensive Income (Loss)
The components of accumulated other comprehensive loss were as follows (in millions):
 
December 30,
2018
 
December 31,
2017
Foreign currency translation adjustments
$
1

 
$
1

Unrealized loss on available-for-sale debt securities, net of deferred tax
(2
)
 
(2
)
Total accumulated other comprehensive loss
$
(1
)
 
$
(1
)
v3.10.0.1
Balance Sheet Account Details (Tables)
 12 Months Ended
Dec. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Summary of Debt Securities
Available-for-sale debt securities, included in short-term investments, consisted of the following (in millions):
 
December 30, 2018
 
December 31, 2017
 
Amortized
Cost
 
Gross
Unrealized
Losses
 
Gross
Unrealized
Gains
 
 
Estimated
Fair Value
 
 Amortized
Cost
 
Gross
Unrealized
Losses
 
 
Estimated
Fair Value
Debt securities in government-sponsored entities
$
21

 
$
—

 
$
—

 
$
21

 
$
67

 
$
—

 
$
67

Corporate debt securities
1,060

 
(2
)
 
—

 
1,058

 
423

 
(2
)
 
421

U.S. Treasury securities
1,250

 
(1
)
 
1

 
1,250

 
433

 
(1
)
 
432

Total
$
2,331

 
$
(3
)
 
$
1

 
$
2,329

 
$
923

 
$
(3
)
 
$
920
Summary of Contractual Maturities of Available-for-sale Debt Securities
Contractual maturities of available-for-sale debt securities, as of December 30, 2018, were as follows (in millions):
 
Estimated Fair Value
Due within one year
$
1,618

After one but within five years
711

Total
$
2,329
Summary of Accounts Receivable
Accounts receivable, net consisted of the following (in millions):
 
December 30,
2018
 
December 31,
2017
Trade accounts receivable, gross
$
516

 
$
414

Allowance for doubtful accounts
(2
)
 
(3
)
Total accounts receivable, net
$
514

 
$
411
Summary of Inventory
Inventory consisted of the following (in millions):
 
December 30,
2018
 
December 31,
2017
Raw materials
$
117

 
$
93

Work in process
218

 
188

Finished goods
51

 
52

Total inventory
$
386

 
$
333
Summary of Property and Equipment
The estimated useful lives of the major classes of property and equipment are generally as follows:
 
Estimated Useful Lives
Buildings and leasehold improvements
4 to 20 years
Machinery and equipment
3 to 5 years
Computer hardware and software
3 to 7 years
Furniture and fixtures
7 years
Property and equipment, net consisted of the following (in millions):
 
December 30,
2018
 
December 31,
2017
Leasehold improvements
$
567

 
$
331

Machinery and equipment
382

 
316

Computer hardware and software
217

 
185

Furniture and fixtures
45

 
34

Buildings
285

 
155

Construction in progress
100

 
326

Total property and equipment, gross
1,596

 
1,347

Accumulated depreciation
(521
)
 
(416
)
Total property and equipment, net
$
1,075

 
$
931
Summary of Accrued Liabilities
Accrued liabilities consisted of the following (in millions):
 
December 30,
2018
 
December 31,
2017
Contract liabilities, current portion
$
175

 
$
150

Accrued compensation expenses
193

 
177

Accrued taxes payable
82

 
50

Other, including warranties (a)
63

 
55

Total accrued liabilities
$
513

 
$
432



(a) Changes in the reserve for product warranties from January 3, 2016 through December 30, 2018 were as follows (in millions):
 
Warranty Reserve
Balance as of January 3, 2016
$
17

Additions charged to cost of revenue
21

Repairs and replacements
(25
)
Balance as of January 1, 2017
13

Additions charged to cost of revenue
26

Repairs and replacements
(22
)
Balance as of December 31, 2017
17

Additions charged to cost of revenue
27

Repairs and replacements
(25
)
Balance as of December 30, 2018
$
19
Summary of Changes in Reserve for Product Warranties
Changes in the reserve for product warranties from January 3, 2016 through December 30, 2018 were as follows (in millions):
 
Warranty Reserve
Balance as of January 3, 2016
$
17

Additions charged to cost of revenue
21

Repairs and replacements
(25
)
Balance as of January 1, 2017
13

Additions charged to cost of revenue
26

Repairs and replacements
(22
)
Balance as of December 31, 2017
17

Additions charged to cost of revenue
27

Repairs and replacements
(25
)
Balance as of December 30, 2018
$
19
Summary of Activity of Redeemable Noncontrolling Interests
The activity of the redeemable noncontrolling interests from January 3, 2016 through December 30, 2018 was as follows (in millions):
 
Redeemable Noncontrolling Interests
Balance as of January 3, 2016
$
33

Cash contributions
9

Vesting of redeemable equity awards
2

Net loss attributable to noncontrolling interests
(21
)
Adjustment up to the redemption value
21

Balance as of January 1, 2017
44

Amount released from escrow
79

Vesting of redeemable equity awards
13

Net loss attributable to noncontrolling interests
(41
)
Adjustment up to the redemption value
136

Deconsolidation of GRAIL
(11
)
Balance as of December 31, 2017
220

Vesting of redeemable equity awards
2

Net loss attributable to noncontrolling interests
(34
)
Adjustment down to the redemption value
(127
)
Balance as of December 30, 2018
$
61
v3.10.0.1
Intangible Assets, Goodwill, and Acquisitions (Tables)
 12 Months Ended
Dec. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]  
Summary of Finite-lived Intangible Assets
Identifiable intangible assets consisted of the following (in millions):
 
December 30, 2018
 
December 31, 2017
 
Gross
Carrying
Amount
 
Accumulated
Amortization
 
Intangibles,
Net
 
Gross
Carrying
Amount
 
Accumulated
Amortization
 
Intangibles,
Net
Licensed technologies
$
95

 
$
(83
)
 
$
12

 
$
95

 
$
(74
)
 
$
21

Core technologies
331

 
(172
)
 
159

 
300

 
(161
)
 
139

Customer relationships
32

 
(27
)
 
5

 
32

 
(25
)
 
7

License agreements
14

 
(9
)
 
5

 
14

 
(8
)
 
6

Trade name
9

 
(5
)
 
4

 
7

 
(5
)
 
2

Total intangible assets, net
$
481

 
$
(296
)
 
$
185

 
$
448

 
$
(273
)
 
$
175
Summary of the Estimated Annual Amortization of Finite-lived Intangible Assets
The estimated annual amortization of intangible assets for the next five years is shown in the following table (in millions). Actual amortization expense to be reported in future periods could differ from these estimates as a result of acquisitions, divestitures, and asset impairments, among other factors.
 
Estimated Annual Amortization
2019
$
37

2020
30

2021
26

2022
22

2023
20

Thereafter
50

Total
$
185
Schedule of Goodwill
Changes to goodwill from January 1, 2017 through December 30, 2018 were as follows (in millions):
 
Goodwill
Balance as of January 1, 2017
$
776

GRAIL deconsolidation
(5
)
Balance as of December 31, 2017
771

Acquisitions
60

Balance as of December 30, 2018
$
831
v3.10.0.1
Fair Value Measurements (Tables)
 12 Months Ended
Dec. 30, 2018
Fair Value Disclosures [Abstract]  
Summary of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on a Recurring Basis
The following table presents the hierarchy for assets and liabilities measured at fair value on a recurring basis as of December 30, 2018 and December 31, 2017 (in millions):
 
December 30, 2018
 
December 31, 2017
 
Level 1
 
Level 2
 
Level 3
 
Total
 
Level 1
 
Level 2
 
Level 3
 
Total
Assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Money market funds (cash equivalents)
$
832

 
$
—

 
$
—

 
$
832

 
$
957

 
$
—

 
$
—

 
$
957

Debt securities in government-sponsored entities
—

 
21

 
—

 
21

 
—

 
67

 
—

 
67

Corporate debt securities
—

 
1,058

 
—

 
1,058

 
—

 
421

 
—

 
421

U.S. Treasury securities
1,250

 
—

 
—

 
1,250

 
432

 
—

 
—

 
432

Marketable equity security
39

 
—

 
—

 
39

 
—

 
—

 
—

 
—

Deferred compensation plan assets
—

 
34

 
—

 
34

 
—

 
35

 
—

 
35

Total assets measured at fair value
$
2,121

 
$
1,113

 
$
—

 
$
3,234

 
$
1,389

 
$
523

 
$
—

 
$
1,912

Liabilities:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Deferred compensation plan liability
$
—

 
$
33

 
$
—

 
$
33

 
—

 
$
33

 
$
—

 
$
33
v3.10.0.1
Debt and Other Commitments (Tables)
 12 Months Ended
Dec. 30, 2018
Debt Disclosure [Abstract]  
Schedule of Debt Obligations
Debt obligations consisted of the following (dollars in millions):
 
December 30,
2018
 
December 31,
2017
Principal amount of 2023 Notes outstanding
$
750

 
$
—

Principal amount of 2021 Notes outstanding
517

 
517

Principal amount of 2019 Notes outstanding
633

 
633

Unamortized discount of liability component of convertible senior notes
(175
)
 
(75
)
       Net carrying amount of liability component of convertible senior notes
1,725

 
1,075

Obligations under financing leases
269

 
113

Other
3

 
4

Less: current portion
(1,107
)
 
(10
)
       Long-term debt
$
890

 
$
1,182

Carrying value of equity component of convertible senior notes, net of debt issuance costs
$
287

 
$
161

Fair value of convertible senior notes outstanding (Level 2)
$
2,222

 
$
1,305

Weighted average remaining amortization period of discount on the liability component of convertible senior notes
3.9 years

 
2.8 years
Summary of Annual Future Minimum Payments under Leases
As of December 30, 2018, annual future minimum payments of our operating leases and build-to-suit leases, which include those leases accounted for as a financing obligation, were as follows (in millions):
 
Operating
Leases
 
Sublease
Income
 
Net Operating
Leases
 
Build-to-suit Leases
2019
$
59

 
$
(11
)
 
$
48

 
$
18

2020
64

 
(11
)
 
53

 
21

2021
61

 
(11
)
 
50

 
21

2022
61

 
(12
)
 
49

 
22

2023
61

 
(11
)
 
50

 
22

Thereafter
439

 
(12
)
 
427

 
179

Total minimum lease payments
$
745

 
$
(68
)
 
$
677

 
$
283
Summary of Annual Future Minimum Payments for Noncancelable Purchase Obligations
Annual minimum payments for noncancelable purchase obligations as of December 30, 2018 were as follows (in millions):
 
Minimum Payments
2019
$
93

2020
20

Total
$
113
v3.10.0.1
Stockholders' Equity (Tables)
 12 Months Ended
Dec. 30, 2018
Equity [Abstract]  
Summary of Restricted Stock Activity and Related Information, Restricted Stock

Restricted stock activity from January 3, 2016 through December 30, 2018 was as follows (units in thousands):
 
Restricted
Stock Units
(RSU)
 
Performance
Stock Units
(PSU)(1)
 
Weighted-Average Grant-
Date Fair Value per Share
 
 
 
RSU
 
PSU
Outstanding at January 3, 2016
2,206

 
583

 
$
131.80

 
$
169.41

Awarded
1,245

 
172

 
$
132.47

 
$
113.56

Vested
(928
)
 
(199
)
 
$
105.49

 
$
148.99

Cancelled
(230
)
 
(96
)
 
$
139.74

 
$
163.05

Outstanding at January 1, 2017
2,293

 
460

 
$
141.80

 
$
158.66

Awarded
879

 
238

 
$
207.38

 
$
191.53

Vested
(861
)
 
(92
)
 
$
131.62

 
$
189.09

Cancelled
(226
)
 
(64
)
 
$
149.03

 
$
173.83

Outstanding at December 31, 2017
2,085

 
542

 
$
172.92

 
$
166.15

Awarded
655

 
336

 
$
322.04

 
$
232.08

Vested
(731
)
 
(188
)
 
$
170.50

 
$
176.15

Cancelled
(169
)
 
(30
)
 
$
172.30

 
$
162.54

Outstanding at December 30, 2018
1,840

 
660

 
$
227.00

 
$
196.99

______________________________________
(1)
The number of units reflect the estimated number of shares to be issued at the end of the performance period.
Summary of Restricted Stock Activity and Related Information, Performance Units

Restricted stock activity from January 3, 2016 through December 30, 2018 was as follows (units in thousands):
 
Restricted
Stock Units
(RSU)
 
Performance
Stock Units
(PSU)(1)
 
Weighted-Average Grant-
Date Fair Value per Share
 
 
 
RSU
 
PSU
Outstanding at January 3, 2016
2,206

 
583

 
$
131.80

 
$
169.41

Awarded
1,245

 
172

 
$
132.47

 
$
113.56

Vested
(928
)
 
(199
)
 
$
105.49

 
$
148.99

Cancelled
(230
)
 
(96
)
 
$
139.74

 
$
163.05

Outstanding at January 1, 2017
2,293

 
460

 
$
141.80

 
$
158.66

Awarded
879

 
238

 
$
207.38

 
$
191.53

Vested
(861
)
 
(92
)
 
$
131.62

 
$
189.09

Cancelled
(226
)
 
(64
)
 
$
149.03

 
$
173.83

Outstanding at December 31, 2017
2,085

 
542

 
$
172.92

 
$
166.15

Awarded
655

 
336

 
$
322.04

 
$
232.08

Vested
(731
)
 
(188
)
 
$
170.50

 
$
176.15

Cancelled
(169
)
 
(30
)
 
$
172.30

 
$
162.54

Outstanding at December 30, 2018
1,840

 
660

 
$
227.00

 
$
196.99

______________________________________
(1)
The number of units reflect the estimated number of shares to be issued at the end of the performance period.
Summary of Pre-tax Intrinsic Values of Vested Restricted Stock
Pre-tax intrinsic values and fair value of vested restricted stock was as follows (in millions):
 
Years Ended
 
December 30,
2018
 
December 31,
2017
 
January 1,
2017
Pre-tax intrinsic value of outstanding restricted stock:
 
 
 
 
 
RSU
$
549

 
$
456

 
$
294

PSU
$
197

 
$
118

 
$
59

 
 
 
 
 
 
Fair value of restricted stock vested:
 
 
 
 
 
RSU
$
125

 
$
113

 
$
98

PSU
$
33

 
$
17

 
$
30
Summary of Total Fair Value of Vested Restricted Stock
Pre-tax intrinsic values and fair value of vested restricted stock was as follows (in millions):
 
Years Ended
 
December 30,
2018
 
December 31,
2017
 
January 1,
2017
Pre-tax intrinsic value of outstanding restricted stock:
 
 
 
 
 
RSU
$
549

 
$
456

 
$
294

PSU
$
197

 
$
118

 
$
59

 
 
 
 
 
 
Fair value of restricted stock vested:
 
 
 
 
 
RSU
$
125

 
$
113

 
$
98

PSU
$
33

 
$
17

 
$
30
Summary of Stock Option Activity Under all Stock Option Plans
Stock option activity from January 3, 2016 through December 30, 2018 was as follows:
 
Options
(in thousands)
 
Weighted-
Average
Exercise Price
Outstanding at January 3, 2016
1,599

 
$
41.95

Exercised
(552
)
 
$
29.41

Cancelled
(2
)
 
$
46.35

Outstanding at January 1, 2017
1,045

 
$
48.56

Exercised
(723
)
 
$
49.31

Outstanding at December 31, 2017
322

 
$
46.93

Exercised
(130
)
 
$
35.68

Outstanding and exercisable at December 30, 2018
192

 
$
54.52
Summary of Share-based Compensation Expense for all Stock Awards
Share-based compensation expense reported in our consolidated statements of income was as follows (in millions):
 
Years Ended
 
December 30,
2018
 
December 31,
2017
 
January 1,
2017
Cost of product revenue
$
16

 
$
12

 
$
9

Cost of service and other revenue
3

 
2

 
2

Research and development
60

 
51

 
42

Selling, general and administrative
114

 
99

 
76

Share-based compensation expense, before taxes
193

 
164

 
129

Related income tax benefits
(39
)
 
(48
)
 
(41
)
Share-based compensation expense, net of taxes
$
154

 
$
116

 
$
88
Summary of Assumptions used to Estimate the Weighted-Average Fair Value Per Share for Stock Purchase under the Employee Stock Purchase Plan
The assumptions used for the specified reporting periods and the resulting estimates of weighted-average fair value per share for stock purchased under the ESPP were as follows:
 
Years Ended
 
December 30,
2018
 
December 31,
2017
 
January 1,
2017
Risk-free interest rate
1.22% - 2.45%

 
0.50% - 1.22%

 
0.40% - 0.50%

Expected volatility
29% - 39%

 
29% - 44%

 
40% - 44%

Expected term
0.5 - 1.0 year

 
0.5 - 1.0 year

 
0.5 - 1.0 year

Expected dividends
0
%
 
0
%
 
0
%
Weighted-average grant-date fair value per share
$
61.59

 
$
46.81

 
$
48.29
v3.10.0.1
Income Taxes (Tables)
 12 Months Ended
Dec. 30, 2018
Income Tax Disclosure [Abstract]  
Summary of Income before Income Taxes by Region
Income before income taxes summarized by region was as follows (in millions):
 
Years Ended
 
December 30,
2018
 
December 31,
2017
 
January 1,
2017
United States
$
54

 
$
458

 
$
120

Foreign
840

 
585

 
441

Total income before income taxes
$
894

 
$
1,043

 
$
561
Summary of Provision for Income Taxes
The provision for income taxes consisted of the following (in millions):
 
Years Ended
 
December 30,
2018
 
December 31,
2017
 
January 1,
2017
Current:
 

 
 

 
 

Federal
$
47

 
$
259

 
$
71

State
15

 
21

 
10

Foreign
68

 
51

 
45

Total current provision
130

 
331

 
126

Deferred:
 

 
 

 
 

Federal
—

 
36

 
16

State
(16
)
 
—

 
(5
)
Foreign
(2
)
 
(2
)
 
(4
)
Total deferred (benefit) expense
(18
)
 
34

 
7

Total tax provision
$
112

 
$
365

 
$
133
Summary of Reconciliation of Provision for Income Taxes to Amount Computed by Applying the Federal Statutory Rate
The provision for income taxes reconciles to the amount computed by applying the federal statutory rate to income before taxes as follows (in millions):
 
Years Ended
 
December 30,
2018
 
December 31,
2017
 
January 1,
2017
Tax at federal statutory rate
$
188

 
$
365

 
$
196

State, net of federal benefit
13

 
19

 
10

Research and other credits
(23
)
 
(12
)
 
(13
)
Change in valuation allowance
(12
)
 
12

 
5

Impact of foreign operations
(59
)
 
(130
)
 
(86
)
Cost sharing adjustment
—

 
—

 
(7
)
Investments in consolidated variable interest entities
9

 
(3
)
 
25

Impact of U.S. Tax Reform
11

 
150

 
—

Stock compensation
(24
)
 
(41
)
 
3

Other
9

 
5

 
—

Total tax provision
$
112

 
$
365

 
$
133
Summary of Significant Components of Deferred Tax Assets and Liabilities
Significant components of deferred tax assets and liabilities were as follows (in millions):
 
December 30,
2018
 
December 31,
2017
Deferred tax assets:
 

 
 

Net operating losses
$
26

 
$
18

Tax credits
63

 
57

Other accruals and reserves
28

 
25

Stock compensation
20

 
19

Deferred rent
30

 
28

Cost sharing adjustment
21

 
21

Other amortization
13

 
12

Lease obligation
70

 
27

Investments
1

 
13

Other
28

 
26

Total gross deferred tax assets
300

 
246

Valuation allowance on deferred tax assets
(15
)
 
(25
)
Total deferred tax assets
285

 
221

Deferred tax liabilities:
 

 
 

Purchased intangible amortization
(32
)
 
(26
)
Convertible debt
(41
)
 
(18
)
Property and equipment
(94
)
 
(44
)
Investments
(45
)
 
(40
)
Other
(3
)
 
(5
)
Total deferred tax liabilities
(215
)
 
(133
)
Deferred tax assets, net
$
70

 
$
88
Summary of the Gross Amount of Uncertain Tax Positions
The following table summarizes the gross amount of our uncertain tax positions (in millions):
 
December 30,
2018
 
December 31,
2017
 
January 1,
2017
Balance at beginning of year
$
79

 
$
65

 
$
56

Increases related to prior year tax positions
1

 
2

 
—

Decreases related to prior year tax positions
(1
)
 
—

 
(2
)
Increases related to current year tax positions
12

 
14

 
13

Decreases related to lapse of statute of limitations
(3
)
 
(2
)
 
(2
)
Balance at end of year
$
88

 
$
79

 
$
65
v3.10.0.1
Segment Information and Geographic Data (Tables)
 12 Months Ended
Dec. 30, 2018
Segment Reporting [Abstract]  
Summary of Operating Performance and Assets by Segment
The following table presents the operating performance of each reportable segment (in millions):
 
Years Ended
 
December 30,
2018
 
December 31,
2017
 
January 1,
2017
Revenue:
 
 
 
 
 
Core Illumina
$
3,334

 
$
2,754

 
$
2,428

Consolidated VIEs
10

 
6

 
—

Eliminations
(11
)
 
(8
)
 
(30
)
Consolidated revenue
$
3,333

 
$
2,752

 
$
2,398

 
 
 
 
 
 
Depreciation and amortization:
 
 
 
 
 
Core Illumina
$
175

 
$
153

 
$
138

Consolidated VIEs
6

 
6

 
4

Eliminations
(2
)
 
(3
)
 
(1
)
Consolidated depreciation and amortization
$
179

 
$
156

 
$
141

 
 
 
 
 
 
Income (loss) from operations:
 
 
 
 
 
Core Illumina
$
970

 
$
696

 
$
684

Consolidated VIEs
(90
)
 
(92
)
 
(81
)
Eliminations
3

 
2

 
(16
)
Consolidated income from operations
$
883

 
$
606

 
$
587


Other income (expense), net primarily relates to Core Illumina and we do not allocate income taxes to our segments.

The following table presents the total assets and capital expenditures of each reportable segment (in millions):
 
Years Ended
 
December 30,
2018
 
December 31,
2017
 
January 1,
2017
Total assets:
 
 
 
 
 
Core Illumina
$
6,912

 
$
5,223

 
$
4,167

Consolidated VIEs
154

 
45

 
180

Eliminations
(107
)
 
(11
)
 
(66
)
Consolidated total assets
$
6,959

 
$
5,257

 
$
4,281

 
 
 
 
 
 
Capital expenditures:
 
 
 
 
 
Core Illumina
$
294

 
$
306

 
$
238

Consolidated VIEs
2

 
4

 
22

Consolidated capital expenditures
$
296

 
$
310

 
$
260
Summary of Net Long-lived Assets Consisting of Property and Equipment by Region
Net long-lived assets exclude goodwill and other intangible assets since they are not allocated on a geographic basis. We had net long-lived assets, consisting of property and equipment, in the following regions as of December 30, 2018 and December 31, 2017 (in millions):
 
December 30,
2018
 
December 31,
2017
United States
$
907

 
$
828

Singapore
96

 
54

United Kingdom
62

 
43

Other countries
10

 
6

Total
$
1,075

 
$
931
v3.10.0.1
Quarterly Financial Information (unaudited) (Tables)
 12 Months Ended
Dec. 30, 2018
Quarterly Financial Information Disclosure [Abstract]  
Summary of Quarterly Data
Summarized quarterly data for fiscal years 2018 and 2017 are as follows (in millions, except per share amounts):
 
First Quarter
 
Second Quarter
 
Third Quarter
 
Fourth Quarter
2018
 

 
 

 
 

 
 

Total revenue
$
782

 
$
830

 
$
853

 
$
867

Gross profit
$
538

 
$
575

 
$
597

 
$
590

Consolidated net income
$
197

 
$
200

 
$
188

 
$
198

Net income attributable to Illumina stockholders
$
208

 
$
209

 
$
199

 
$
210

Earnings per share attributable to Illumina stockholders:
 
 
 
 
 
 
 
Basic
$
1.42

 
$
1.42

 
$
1.35

 
$
1.43

Diluted
$
1.41

 
$
1.41

 
$
1.33

 
$
1.41

2017
 
 
 
 
 
 
 
Total revenue
$
598

 
$
662

 
$
714

 
$
778

Gross profit
$
368

 
$
434

 
$
482

 
$
542

Consolidated net income
$
348

 
$
120

 
$
152

 
$
58

Net income attributable to Illumina stockholders (a)
$
367

 
$
128

 
$
163

 
$
68

Earnings per share attributable to Illumina stockholders:
 
 
 
 
 
 
 
Basic
$
2.50

 
$
0.87

 
$
1.12

 
$
0.47

Diluted
$
2.48

 
$
0.87

 
$
1.11

 
$
0.46


Certain amounts may not recalculate using the rounded amounts provided.

(a) First quarter of 2017 includes the results of GRAIL through February 28, 2017, the date of deconsolidation. Refer to note “2. Balance Sheet Account Details” for further discussion.
v3.10.0.1
Organization and Summary of Significant Accounting Policies - Narrative - Recently Adopted and Issued Accounting Pronouncements (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 30, 2018
Jan. 01, 2017
Dec. 31, 2018
Apr. 02, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]        
Unrealized tax benefits associated with share-based compensation       $ 45
Increase in cash flows from operating activities due to adoption of ASU 2016-09   $ 91    
Interest portion of lease expense $ 13      
Subsequent Event        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]        
Net recognition of additional total assets due to the adoption of ASU 2016-02     $ 329  
Net recognition of additional total liabilities due to the adoption of ASU 2016-02     $ 354  
v3.10.0.1
Organization and Summary of Significant Accounting Policies - Narrative - Concentrations of Risk (Details)
 12 Months Ended
Dec. 30, 2018
Dec. 31, 2017
Jan. 01, 2017
Credit concentration risk | Investment portfolio      
Concentration Risk [Line Items]      
Maximum investment portfolio credit exposure 5.00%    
Credit concentration risk | Issue size      
Concentration Risk [Line Items]      
Maximum investment portfolio credit exposure 5.00%    
Industry credit concentration risk | Investment portfolio      
Concentration Risk [Line Items]      
Maximum investment portfolio credit exposure 30.00%    
Geographic concentration risk | Sales revenue, net | Outside the United States      
Concentration Risk [Line Items]      
Concentration percent 47.00% 45.00% 46.00%
Geographic concentration risk | Accounts receivable | Outside the United States      
Concentration Risk [Line Items]      
Concentration percent 44.00% 48.00%  
v3.10.0.1
Organization and Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Major Classes of Property and Equipment (Details)
 12 Months Ended
Dec. 30, 2018
Building and leasehold improvements | Minimum  
Property, Plant and Equipment [Line Items]  
Useful life 4 years
Building and leasehold improvements | Maximum  
Property, Plant and Equipment [Line Items]  
Useful life 20 years
Machinery and equipment | Minimum  
Property, Plant and Equipment [Line Items]  
Useful life 3 years
Machinery and equipment | Maximum  
Property, Plant and Equipment [Line Items]  
Useful life 5 years
Computer hardware and software | Minimum  
Property, Plant and Equipment [Line Items]  
Useful life 3 years
Computer hardware and software | Maximum  
Property, Plant and Equipment [Line Items]  
Useful life 7 years
Furniture and fixtures  
Property, Plant and Equipment [Line Items]  
Useful life 7 years
v3.10.0.1
Organization and Summary of Significant Accounting Policies - Narrative - Goodwill, Intangible Assets and Other Long-Lived Assets (Details)
$ in Millions
 12 Months Ended
Dec. 31, 2017
USD ($)
Finite-Lived Intangible Assets [Line Items]  
Impairment of in-process research and development $ 5
Cost of Sales  
Finite-Lived Intangible Assets [Line Items]  
Impairment of finite-lived intangible assets $ 18
v3.10.0.1
Organization and Summary of Significant Accounting Policies - Narrative - Derivatives (Details) - USD ($)
$ in Millions
Dec. 30, 2018
Dec. 31, 2017
Foreign exchange forward | Not designated as hedging instrument    
Derivative Instruments, Gain (Loss) [Line Items]    
Notional amount of outstanding forward contracts $ 122 $ 88
v3.10.0.1
Organization and Summary of Significant Accounting Policies - Narrative - Warranties (Details)
 12 Months Ended
Dec. 30, 2018
Instruments  
Product Warranty Liability [Line Items]  
Warranty period 1 year
Consumables | Minimum  
Product Warranty Liability [Line Items]  
Warranty period 6 months
Consumables | Maximum  
Product Warranty Liability [Line Items]  
Warranty period 12 months
v3.10.0.1
Organization and Summary of Significant Accounting Policies - Narrative - Revenue Recognition (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 30, 2018
Dec. 31, 2017
Revenue from External Customer [Line Items]    
Expected timing of satisfaction, period 1 year  
Remaining performance obligations $ 909  
Percent of remaining performance obligations 80.00%  
Period of time average selling prices are observed to establish best estimate of selling price 12 months  
Contract liabilities $ 206 $ 181
Contract liabilities, current portion 175 $ 150
Recognized revenue, previously deferred $ 146  
Minimum    
Revenue from External Customer [Line Items]    
Product or service delivery period 3 months  
Maximum    
Revenue from External Customer [Line Items]    
Product or service delivery period 6 months  
v3.10.0.1
Organization and Summary of Significant Accounting Policies - Summary of Disaggregated Revenue (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Dec. 30, 2018
Sep. 30, 2018
Jul. 01, 2018
Apr. 01, 2018
Dec. 31, 2017
Oct. 01, 2017
Jul. 02, 2017
Apr. 02, 2017
Dec. 30, 2018
Dec. 31, 2017
Jan. 01, 2017
Revenue from External Customer [Line Items]                      
Revenue $ 867 $ 853 $ 830 $ 782 $ 778 $ 714 $ 662 $ 598 $ 3,333 $ 2,752 $ 2,398
Sequencing                      
Revenue from External Customer [Line Items]                      
Revenue                 2,775 2,293 2,016
Microarray                      
Revenue from External Customer [Line Items]                      
Revenue                 558 459 382
Consumables                      
Revenue from External Customer [Line Items]                      
Revenue                 2,156 1,753 1,543
Consumables | Sequencing                      
Revenue from External Customer [Line Items]                      
Revenue                 1,806 1,468 1,271
Consumables | Microarray                      
Revenue from External Customer [Line Items]                      
Revenue                 350 285 272
Instruments                      
Revenue from External Customer [Line Items]                      
Revenue                 569 515 469
Instruments | Sequencing                      
Revenue from External Customer [Line Items]                      
Revenue                 532 484 450
Instruments | Microarray                      
Revenue from External Customer [Line Items]                      
Revenue                 37 31 19
Other product                      
Revenue from External Customer [Line Items]                      
Revenue                 24 21 20
Other product | Sequencing                      
Revenue from External Customer [Line Items]                      
Revenue                 21 19 18
Other product | Microarray                      
Revenue from External Customer [Line Items]                      
Revenue                 3 2 2
Product revenue                      
Revenue from External Customer [Line Items]                      
Revenue                 2,749 2,289 2,032
Product revenue | Sequencing                      
Revenue from External Customer [Line Items]                      
Revenue                 2,359 1,971 1,739
Product revenue | Microarray                      
Revenue from External Customer [Line Items]                      
Revenue                 390 318 293
Service and other revenue                      
Revenue from External Customer [Line Items]                      
Revenue                 584 463 366
Service and other revenue | Sequencing                      
Revenue from External Customer [Line Items]                      
Revenue                 416 322 277
Service and other revenue | Microarray                      
Revenue from External Customer [Line Items]                      
Revenue                 168 141 89
Americas                      
Revenue from External Customer [Line Items]                      
Revenue                 1,864 1,585 1,367
Europe, Middle East, and Africa                      
Revenue from External Customer [Line Items]                      
Revenue                 851 653 575
Greater China                      
Revenue from External Customer [Line Items]                      
Revenue                 365 292  
Asia-Pacific                      
Revenue from External Customer [Line Items]                      
Revenue                 253 222 456
United States                      
Revenue from External Customer [Line Items]                      
Revenue                 $ 1,779 $ 1,511 $ 1,294
Sales revenue, net | Product concentration risk | Consumables                      
Revenue from External Customer [Line Items]                      
Concentration percent                 65.00% 64.00% 64.00%
Sales revenue, net | Product concentration risk | Instruments                      
Revenue from External Customer [Line Items]                      
Concentration percent                 17.00% 19.00% 20.00%
Sales revenue, net | Product concentration risk | Services                      
Revenue from External Customer [Line Items]                      
Concentration percent                 18.00% 17.00% 15.00%
v3.10.0.1
Organization and Summary of Significant Accounting Policies - Narrative - Share-Based Compensation (Details)
 12 Months Ended
Dec. 30, 2018
Accounting Policies [Abstract]  
Expected dividends 0.00%
v3.10.0.1
Organization and Summary of Significant Accounting Policies - Narrative - Advertising Costs (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 30, 2018
Dec. 31, 2017
Jan. 01, 2017
Accounting Policies [Abstract]      
Advertising expense $ 38 $ 30 $ 20
v3.10.0.1
Organization and Summary of Significant Accounting Policies - Summary of Calculation of Weighted Average Shares used to Calculate Basic and Diluted Earnings Per Share (Details) - shares
shares in Millions
 12 Months Ended
Dec. 30, 2018
Dec. 31, 2017
Jan. 01, 2017
Weighted average shares used to calculate basic and diluted net income per share [Line Items]      
Weighted average shares outstanding 147 146 147
Effect of potentially dilutive common shares from:      
Convertible senior notes 1    
Equity awards 1 2 1
Weighted average shares used in calculating diluted net income per share 149 148 148
v3.10.0.1
Organization and Summary of Significant Accounting Policies - Summary of Components of Accumulated Other Comprehensive Loss (Details) - USD ($)
$ in Millions
Dec. 30, 2018
Dec. 31, 2017
Accumulated Other Comprehensive Income [Line Items]    
Total accumulated other comprehensive loss $ 3,758 $ 2,749
Foreign currency translation adjustments    
Accumulated Other Comprehensive Income [Line Items]    
Total accumulated other comprehensive loss 1 1
Unrealized loss on available-for-sale debt securities, net of deferred tax    
Accumulated Other Comprehensive Income [Line Items]    
Total accumulated other comprehensive loss (2) (2)
AOCI attributable to parent    
Accumulated Other Comprehensive Income [Line Items]    
Total accumulated other comprehensive loss $ (1) $ (1)
v3.10.0.1
Balance Sheet Account Details - Summary of Investments (Details) - USD ($)
$ in Millions
Dec. 30, 2018
Dec. 31, 2017
Available-for-sale debt securities:    
Amortized Cost $ 2,331 $ 923
Gross Unrealized Losses (3) (3)
Gross Unrealized Gains 1  
Estimated Fair Value 2,329 920
Debt securities in government-sponsored entities    
Available-for-sale debt securities:    
Amortized Cost 21 67
Gross Unrealized Losses  
Estimated Fair Value 21 67
Corporate debt securities    
Available-for-sale debt securities:    
Amortized Cost 1,060 423
Gross Unrealized Losses (2) (2)
Estimated Fair Value 1,058 421
U.S. Treasury securities    
Available-for-sale debt securities:    
Amortized Cost 1,250 433
Gross Unrealized Losses (1) (1)
Gross Unrealized Gains 1  
Estimated Fair Value $ 1,250 $ 432
v3.10.0.1
Balance Sheet Account Details - Summary of Contractual Maturities of Available-for-sale Debt Securities (Details) - USD ($)
$ in Millions
Dec. 30, 2018
Dec. 31, 2017
Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract]    
Due within one year $ 1,618  
After one but within five years 711  
Total $ 2,329 $ 920
v3.10.0.1
Balance Sheet Account Details - Narrative - Equity Securities and Venture Fund (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 30, 2018
Dec. 31, 2017
Jan. 01, 2017
Schedule of Investments [Line Items]      
Marketable equity security $ 39    
Marketable equity securities, unrealized gain 21    
Other commitment 100    
Remaining callable capital commitment 69    
Other Assets      
Schedule of Investments [Line Items]      
Equity investments without readily determinable fair value 231 $ 250  
Equity method investments 29 16  
Investee      
Schedule of Investments [Line Items]      
Revenue from transactions with Company's strategic equity investees 143 $ 127 $ 56
Fair value, measurements, recurring      
Schedule of Investments [Line Items]      
Marketable equity security 39    
Level 1 | Fair value, measurements, recurring      
Schedule of Investments [Line Items]      
Marketable equity security $ 39    
v3.10.0.1
Balance Sheet Account Details - Summary of Accounts Receivable (Details) - USD ($)
$ in Millions
Dec. 30, 2018
Dec. 31, 2017
Accounts Receivable, Net [Abstract]    
Trade accounts receivable, gross $ 516 $ 414
Allowance for doubtful accounts (2) (3)
Total accounts receivable, net $ 514 $ 411
v3.10.0.1
Balance Sheet Account Details - Summary of Inventory (Details) - USD ($)
$ in Millions
Dec. 30, 2018
Dec. 31, 2017
Inventory [Abstract]    
Raw materials $ 117 $ 93
Work in process 218 188
Finished goods 51 52
Total inventory $ 386 $ 333
v3.10.0.1
Balance Sheet Account Details - Summary of Property and Equipment (Details) - USD ($)
$ in Millions
Dec. 30, 2018
Dec. 31, 2017
Property, Plant and Equipment [Line Items]    
Total property and equipment, gross $ 1,596 $ 1,347
Accumulated depreciation (521) (416)
Total property and equipment, net 1,075 931
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Total property and equipment, gross 567 331
Machinery and equipment    
Property, Plant and Equipment [Line Items]    
Total property and equipment, gross 382 316
Computer hardware and software    
Property, Plant and Equipment [Line Items]    
Total property and equipment, gross 217 185
Furniture and fixtures    
Property, Plant and Equipment [Line Items]    
Total property and equipment, gross 45 34
Buildings    
Property, Plant and Equipment [Line Items]    
Total property and equipment, gross 285 155
Construction in progress    
Property, Plant and Equipment [Line Items]    
Total property and equipment, gross $ 100 $ 326
v3.10.0.1
Balance Sheet Account Details - Narrative - Property and Equipment (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 30, 2018
Dec. 31, 2017
Jan. 01, 2017
Property, Plant and Equipment [Line Items]      
Non-cash expenditures included in property and equipment, net $ 35 $ 117 $ 220
Build to suit lease liability      
Property, Plant and Equipment [Line Items]      
Non-cash expenditures included in property and equipment, net $ 18 $ 79 $ 193
v3.10.0.1
Balance Sheet Account Details - Summary of Accrued Liabilities (Details) - USD ($)
$ in Millions
Dec. 30, 2018
Dec. 31, 2017
Accrued Liabilities, Current [Abstract]    
Contract liabilities, current portion $ 175 $ 150
Accrued compensation expenses 193 177
Accrued taxes payable 82 50
Other, including warranties 63 55
Total accrued liabilities $ 513 $ 432
v3.10.0.1
Balance Sheet Account Details - Summary of Changes in Reserve for Product Warranties (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 30, 2018
Dec. 31, 2017
Jan. 01, 2017
Changes in Reserve for Product Warranties [Roll Forward]      
Balance as of beginning of period $ 17 $ 13 $ 17
Additions charged to cost of revenue 27 26 21
Repairs and replacements (25) (22) (25)
Balance as of end of period $ 19 $ 17 $ 13
v3.10.0.1
Balance Sheet Account Details - Narrative - Investment in Consolidated Variable Interest Entities (Details) - USD ($)
$ in Millions
 2 Months Ended 12 Months Ended
Feb. 28, 2017
Feb. 28, 2017
Dec. 30, 2018
Dec. 31, 2017
Jan. 01, 2017
Feb. 27, 2017
Jan. 03, 2016
Jul. 31, 2015
Variable Interest Entity [Line Items]                
Payments to acquire additional interest in subsidiaries     $ 100          
Cash and cash equivalents attributable to variable interest entities     $ 1,144 $ 1,225 $ 735   $ 769  
Gain on deconsolidation of GRAIL       453        
Variable Interest Entity, Primary Beneficiary | Helix Holdings I, LLC                
Variable Interest Entity [Line Items]                
Equity ownership interest percentage     50.00%         50.00%
Cash and cash equivalents attributable to variable interest entities     $ 127          
Helix Holdings I, LLC | Variable Interest Entity, Primary Beneficiary                
Variable Interest Entity [Line Items]                
Ownership percentage by noncontrolling interest owners     50.00%          
GRAIL, Inc. | Variable Interest Entity, Primary Beneficiary                
Variable Interest Entity [Line Items]                
Equity ownership interest percentage           52.00%    
Other Assets                
Variable Interest Entity [Line Items]                
Equity investments without readily determinable fair value     $ 231 250        
Other Assets | GRAIL, Inc.                
Variable Interest Entity [Line Items]                
Equity investments without readily determinable fair value     $ 189 $ 185        
GRAIL, Inc.                
Variable Interest Entity [Line Items]                
Ownership percentage 19.00% 19.00%            
Investment voting interest percentage 13.00% 13.00%            
Gain on deconsolidation of GRAIL $ 453              
Remeasurement of retained equity $ 159              
GRAIL, Inc. | Variable Interest Entity, Primary Beneficiary                
Variable Interest Entity [Line Items]                
Percentage of entity's losses absorbed   50.00%     50.00%      
v3.10.0.1
Balance Sheet Account Details - Summary of Activity of Redeemable Noncontrolling Interests (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 30, 2018
Dec. 31, 2017
Jan. 01, 2017
Increase (Decrease) in Redeemable Noncontrolling Interests [Roll Forward]      
Beginning balance $ 220 $ 44 $ 33
Cash contributions     9
Amount released from escrow   79  
Vesting of redeemable equity awards 2 13 2
Net loss attributable to noncontrolling interests (34) (41) (21)
Adjustment up to the redemption value   136 21
Deconsolidation of GRAIL   (11)  
Adjustment down to the redemption value (127)    
Ending balance $ 61 $ 220 $ 44
v3.10.0.1
Intangible Assets, Goodwill, and Acquisitions - Summary of Identifiable Intangible Assets (Details) - USD ($)
$ in Millions
Dec. 30, 2018
Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount $ 481 $ 448
Accumulated Amortization (296) (273)
Intangibles, Net 185 175
Licensed technologies    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 95 95
Accumulated Amortization (83) (74)
Intangibles, Net 12 21
Core technologies    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 331 300
Accumulated Amortization (172) (161)
Intangibles, Net 159 139
Customer relationships    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 32 32
Accumulated Amortization (27) (25)
Intangibles, Net 5 7
License agreements    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 14 14
Accumulated Amortization (9) (8)
Intangibles, Net 5 6
Trade name    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 9 7
Accumulated Amortization (5) (5)
Intangibles, Net $ 4 $ 2
v3.10.0.1
Intangible Assets, Goodwill, and Acquisitions - Summary of the Estimated Annual Amortization of Intangible Assets (Details) - USD ($)
$ in Millions
Dec. 30, 2018
Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]    
2019 $ 37  
2020 30  
2021 26  
2022 22  
2023 20  
Thereafter 50  
Intangibles, Net $ 185 $ 175
v3.10.0.1
Intangible Assets, Goodwill, and Acquisitions - Summary of Changes in Goodwill (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 30, 2018
Dec. 31, 2017
Goodwill [Roll Forward]    
Beginning balance $ 771 $ 776
GRAIL deconsolidation   (5)
Acquisitions 60  
Ending balance $ 831 $ 771
v3.10.0.1
Intangible Assets, Goodwill, and Acquisitions - Goodwill Narrative (Details) - USD ($)
$ in Millions
 12 Months Ended
May 14, 2018
Dec. 30, 2018
Goodwill [Line Items]    
Goodwill, acquired   $ 60
Edico Genome    
Goodwill [Line Items]    
Business acquisition total consideration $ 100  
Goodwill, acquired 56  
Developed technology | Edico Genome    
Goodwill [Line Items]    
Value of intangible assets acquired $ 45  
Weighted-average useful lives (in years) 10 years  
Trade name | Edico Genome    
Goodwill [Line Items]    
Value of intangible assets acquired $ 1  
Weighted-average useful lives (in years) 3 years  
v3.10.0.1
Intangible Assets, Goodwill, and Acquisitions - Merger Agreement (Details) - PacBio
$ / shares in Units, $ in Millions
Nov. 01, 2018
USD ($)
$ / shares
Business Acquisition [Line Items]  
Expected business acquisition total consideration $ 1,200
Expected share price in dollars per share) | $ / shares $ 8.00
Potential fee paid to Illumina if contract terminates $ 43
Potential fee paid by Illumina if contract terminates $ 98
v3.10.0.1
Fair Value Measurements - Summary of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)
$ in Millions
Dec. 30, 2018
Dec. 31, 2017
Assets:    
Debt securities $ 2,329 $ 920
Marketable equity security 39  
Debt securities in government sponsored entities [Member]    
Assets:    
Debt securities 21 67
Corporate debt securities    
Assets:    
Debt securities 1,058 421
U.S. Treasury securities    
Assets:    
Debt securities 1,250 432
Fair value, measurements, recurring    
Assets:    
Marketable equity security 39  
Deferred compensation plan assets 34 35
Total assets measured at fair value 3,234 1,912
Liabilities:    
Deferred compensation plan liability 33 33
Fair value, measurements, recurring | Debt securities in government sponsored entities [Member]    
Assets:    
Debt securities 21 67
Fair value, measurements, recurring | Corporate debt securities    
Assets:    
Debt securities 1,058 421
Fair value, measurements, recurring | U.S. Treasury securities    
Assets:    
Debt securities 1,250 432
Fair value, measurements, recurring | Money market funds (cash equivalents)    
Assets:    
Money market funds (cash equivalents) 832 957
Fair value, measurements, recurring | Level 1    
Assets:    
Marketable equity security 39  
Total assets measured at fair value 2,121 1,389
Fair value, measurements, recurring | Level 1 | U.S. Treasury securities    
Assets:    
Debt securities 1,250 432
Fair value, measurements, recurring | Level 1 | Money market funds (cash equivalents)    
Assets:    
Money market funds (cash equivalents) 832 957
Fair value, measurements, recurring | Level 2    
Assets:    
Deferred compensation plan assets 34 35
Total assets measured at fair value 1,113 523
Liabilities:    
Deferred compensation plan liability 33 33
Fair value, measurements, recurring | Level 2 | Debt securities in government sponsored entities [Member]    
Assets:    
Debt securities 21 67
Fair value, measurements, recurring | Level 2 | Corporate debt securities    
Assets:    
Debt securities $ 1,058 $ 421
v3.10.0.1
Debt and Other Commitments - Summary of Debt Obligations (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 30, 2018
Dec. 31, 2017
Aug. 21, 2018
Jun. 29, 2014
Debt Instrument [Line Items]        
Obligations under financing leases $ 269 $ 113    
Other 3 4    
Less: current portion (1,107) (10)    
Long-term debt 890 1,182    
Convertible Debt        
Debt Instrument [Line Items]        
Unamortized discount of liability component of convertible senior notes (175) (75)    
Net carrying amount of liability component of convertible senior notes 1,725 1,075    
Carrying value of equity component of convertible senior notes, net of debt issuance costs $ 287 $ 161    
Weighted average remaining amortization period of discount on the liability component of convertible senior notes 3 years 11 months 2 years 9 months    
Convertible Debt | 2023        
Debt Instrument [Line Items]        
Principal amount of notes outstanding $ 750   $ 750  
Convertible Debt | 2021        
Debt Instrument [Line Items]        
Principal amount of notes outstanding 517 $ 517   $ 517
Convertible Debt | 2019        
Debt Instrument [Line Items]        
Principal amount of notes outstanding 633 633   $ 633
Level 2 | Convertible Debt        
Debt Instrument [Line Items]        
Fair value of convertible senior notes outstanding (Level 2) $ 2,222 $ 1,305    
v3.10.0.1
Debt and Other Commitments - Debt Narrative (Details)
$ / shares in Units, $ in Millions
 1 Months Ended 12 Months Ended
Aug. 21, 2018
USD ($)
day
$ / shares
Jun. 29, 2014
USD ($)
day
$ / shares
Dec. 30, 2018
USD ($)
Dec. 31, 2017
USD ($)
Debt Instrument [Line Items]        
Additional paid in capital, net of tax     $ 3,290 $ 2,833
Convertible Debt        
Debt Instrument [Line Items]        
Carrying value of equity component of convertible senior notes, net of debt issuance costs     $ 287 161
Convertible Debt | 2023        
Debt Instrument [Line Items]        
Stated rate     0.00%  
Principal amount of notes outstanding $ 750   $ 750  
Proceeds from issuance, net of offering expenses $ 735      
Conversion rate 0.0021845      
Conversion price (in dollars per share) | $ / shares $ 457.77      
Threshold common stock trading days | day 20      
Threshold consecutive common stock trading days | day 30      
Threshold percentage of common stock price trigger 130.00%      
Threshold note trading days | day 5      
Threshold consecutive note trading days | day 10      
Threshold percentage of note price trigger 98.00%      
Observation period for the observation value 20 days      
Convertible stock, conversion price (in dollars per share) | $ / shares $ 595.10      
Effective interest rate used to measure fair value of convertible senior note 3.70%      
Debt, fair value $ 624      
Additional paid in capital, before tax 126      
Additional paid in capital, net of tax $ 93      
Convertible Debt | 2019        
Debt Instrument [Line Items]        
Stated rate     0.00%  
Principal amount of notes outstanding   $ 633 $ 633 633
Conversion rate   0.0039318    
Conversion price (in dollars per share) | $ / shares   $ 254.34    
Threshold common stock trading days | day   20    
Threshold consecutive common stock trading days | day   30    
Threshold percentage of common stock price trigger   130.00%    
Threshold note trading days | day   5    
Threshold consecutive note trading days | day   10    
Threshold percentage of note price trigger   98.00%    
Effective interest rate used to measure fair value of convertible senior note   2.90%    
If-converted value in excess of principal     $ 150  
Convertible Debt | 2021        
Debt Instrument [Line Items]        
Stated rate   0.50% 0.50%  
Principal amount of notes outstanding   $ 517 $ 517 $ 517
Conversion rate   0.0039318    
Conversion price (in dollars per share) | $ / shares   $ 254.34    
Threshold common stock trading days | day   20    
Threshold consecutive common stock trading days | day   30    
Threshold percentage of common stock price trigger   130.00%    
Threshold note trading days | day   5    
Threshold consecutive note trading days | day   10    
Threshold percentage of note price trigger   98.00%    
Effective interest rate used to measure fair value of convertible senior note   3.50%    
If-converted value in excess of principal     $ 122  
Convertible Debt | 2019 and 2021        
Debt Instrument [Line Items]        
Principal amount of notes outstanding   $ 1,150    
Proceeds from issuance, net of offering expenses   $ 1,132    
Observation period for the observation value   20 days    
Fair value of liability component, upon issuance   $ 972    
Carrying value of equity component of convertible senior notes, net of debt issuance costs   161    
Cash proceeds   $ 1,133    
v3.10.0.1
Debt and Other Commitments - Leases Narrative (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 30, 2018
Dec. 31, 2017
Jan. 01, 2017
Feb. 28, 2017
Other Commitments [Line Items]        
Obligations under financing leases $ 269 $ 113    
Build-to-suit lease liability   144    
Rent expense 55 46 $ 46  
Interest portion of lease expense 13      
Deferred rent 123 115    
Long-term portion, deferred rent 119 $ 113    
Construction in Progress and Build to Suit Lease Liability        
Other Commitments [Line Items]        
Obligations under financing leases $ 165      
GRAIL, Inc.        
Other Commitments [Line Items]        
Build-to-suit lease liability       $ 58
Build to suit lease, asset under construction       $ 58
v3.10.0.1
Debt and Other Commitments - Summary of Annual Future Minimum Payments under Leases (Details)
$ in Millions
Dec. 30, 2018
USD ($)
Operating Leases  
2019 $ 59
2020 64
2021 61
2022 61
2023 61
Thereafter 439
Total minimum lease payments 745
Sublease Income  
2019 (11)
2020 (11)
2021 (11)
2022 (12)
2023 (11)
Thereafter (12)
Total minimum lease payments (68)
Net Operating Leases  
2019 48
2020 53
2021 50
2022 49
2023 50
Thereafter 427
Total minimum lease payments 677
Build-to-suit Leases  
2019 18
2020 21
2021 21
2022 22
2023 22
Thereafter 179
Total minimum lease payments $ 283
v3.10.0.1
Debt and Other Commitments - Summary of Annual Minimum Payments for Noncancelable Purchase Obligations (Details)
$ in Millions
Dec. 30, 2018
USD ($)
Debt Disclosure [Abstract]  
2019 $ 93
2020 20
Total $ 113
v3.10.0.1
Stockholders' Equity - Narrative - Stockholders' Equity (Details)
shares in Millions
Dec. 30, 2018
shares
2015 Stock and Incentive Compensation Plan  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Shares available for issuance 4.7
v3.10.0.1
Stockholders' Equity - Narrative - Restricted Stock (Details)
 12 Months Ended
Dec. 30, 2018
RSU  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Vesting period 4 years
PSU  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Vesting period 3 years
PSU | Maximum  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Vesting percent 150.00%
v3.10.0.1
Stockholders' Equity - Summary of Restricted Stock Activity and Related Information (Details) - $ / shares
shares in Thousands
 12 Months Ended
Dec. 30, 2018
Dec. 31, 2017
Jan. 01, 2017
Restricted stock units (RSU)      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]      
Outstanding at period start (in shares) 2,085 2,293 2,206
Awarded (in shares) 655 879 1,245
Vested (in shares) (731) (861) (928)
Cancelled (in shares) (169) (226) (230)
Outstanding at period end (in shares) 1,840 2,085 2,293
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]      
Weighted-Average Grant Date Fair Value per Share, Outstanding at period start (in dollars per share) $ 172.92 $ 141.80 $ 131.80
Weighted-Average Grant Date Fair Value per Share, Awarded (in dollars per share) 322.04 207.38 132.47
Weighted-Average Grant Date Fair Value per Share, Vested (in dollars per share) 170.50 131.62 105.49
Weighted-Average Grant Date Fair Value per Share, Cancelled (in dollars per share) 172.30 149.03 139.74
Weighted-Average Grant Date Fair Value per Share, Outstanding at period end (in dollars per share) $ 227.00 $ 172.92 $ 141.80
Performance stock units (PSU)      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]      
Outstanding at period start (in shares) 542 460 583
Awarded (in shares) 336 238 172
Vested (in shares) (188) (92) (199)
Cancelled (in shares) (30) (64) (96)
Outstanding at period end (in shares) 660 542 460
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]      
Weighted-Average Grant Date Fair Value per Share, Outstanding at period start (in dollars per share) $ 166.15 $ 158.66 $ 169.41
Weighted-Average Grant Date Fair Value per Share, Awarded (in dollars per share) 232.08 191.53 113.56
Weighted-Average Grant Date Fair Value per Share, Vested (in dollars per share) 176.15 189.09 148.99
Weighted-Average Grant Date Fair Value per Share, Cancelled (in dollars per share) 162.54 173.83 163.05
Weighted-Average Grant Date Fair Value per Share, Outstanding at period end (in dollars per share) $ 196.99 $ 166.15 $ 158.66
v3.10.0.1
Stockholders' Equity - Summary of Pre-tax Intrinsic Values and Total Fair Value of Vested Restricted Stock (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 30, 2018
Dec. 31, 2017
Jan. 01, 2017
Restricted stock units (RSU)      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Pre-tax intrinsic value of outstanding restricted stock $ 549 $ 456 $ 294
Fair value of restricted stock vested 125 113 98
Performance stock units (PSU)      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Pre-tax intrinsic value of outstanding restricted stock 197 118 59
Fair value of restricted stock vested $ 33 $ 17 $ 30
v3.10.0.1
Stockholders' Equity - Summary of Stock Option Activity Under all Stock Option Plans (Details) - $ / shares
shares in Thousands
 12 Months Ended
Dec. 30, 2018
Dec. 31, 2017
Jan. 01, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]      
Options, Outstanding at period start (in shares) 322 1,045 1,599
Options, Exercised (in shares) (130) (723) (552)
Options, Cancelled (in shares)     (2)
Options, Outstanding at period end (in shares) 192 322 1,045
Options, Exercisable at period end (in shares) 192    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]      
Weighted-Average Exercise Price, Options, Outstanding at period start (in dollars per share) $ 46.93 $ 48.56 $ 41.95
Weighted-Average Exercise Price, Options, Exercised (in dollars per share) 35.68 49.31 29.41
Weighted-Average Exercise Price, Options, Cancelled (in dollars per share)     46.35
Weighted-Average Exercise Price, Options, Outstanding at period end (in dollars per share) 54.52 $ 46.93 $ 48.56
Weighted-Average Exercise Price, Options, Exercisable at period end (in dollars per share) $ 54.52    
v3.10.0.1
Stockholders' Equity - Narrative - Stock Options (Details) - USD ($)
$ / shares in Units, $ in Millions
 12 Months Ended
Dec. 30, 2018
Dec. 31, 2017
Jan. 01, 2017
Equity [Abstract]      
Weighted average remaining life in years of options outstanding 2 years 5 months    
Weighted average remaining life in years of options exercisable 2 years 5 months    
Aggregate intrinsic value of options outstanding $ 47    
Aggregate intrinsic value of options exercisable $ 47    
Share price (in dollars per share) $ 298.23    
Total intrinsic value of options exercised $ 33 $ 101 $ 71
v3.10.0.1
Stockholders' Equity - Narrative - Employee Stock Purchase Plan (Details) - ESPP - Employee stock - shares
shares in Millions
 12 Months Ended
Dec. 30, 2018
Dec. 31, 2017
Jan. 01, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
ESPP number of shares reserved for issuance 15.5    
Specified percentage of the fair market value of the common stock on the first or last day of the offering period whichever is lower at which stock is purchased 85.00%    
Total shares issued under the ESPP 0.3 0.3 0.2
Shares available for issuance 13.7 14.0  
v3.10.0.1
Stockholders' Equity - Narrative - Share Repurchases (Details) - USD ($)
shares in Millions, $ in Millions
 12 Months Ended
Aug. 21, 2018
Dec. 30, 2018
Dec. 31, 2017
Jan. 01, 2017
Feb. 05, 2019
May 01, 2018
May 04, 2017
Jul. 28, 2016
Class of Stock [Line Items]                
Common stock repurchases   $ 201 $ 251 $ 249        
Common stock                
Class of Stock [Line Items]                
Repurchase of common shares (in shares) 0.3 0.6 1.4 1.8        
Common stock repurchases $ 103 $ 201 $ 251 $ 249        
Dollar amount remaining in authorized stock repurchase program   $ 49            
Common stock | July 2016 Share Repurchase Plan                
Class of Stock [Line Items]                
Stock repurchase program authorized amount               $ 250
Common stock | May 2017 Share Repurchase Plan                
Class of Stock [Line Items]                
Stock repurchase program authorized amount             $ 250  
Common stock | May 2018 Share Repurchase Plan                
Class of Stock [Line Items]                
Stock repurchase program authorized amount           $ 150    
Subsequent Event | Common stock | February 2019 Share Repurchase Plan                
Class of Stock [Line Items]                
Stock repurchase program authorized amount         $ 550      
v3.10.0.1
Stockholders' Equity - Summary of Share-based Compensation Expense for all Stock Awards (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 30, 2018
Dec. 31, 2017
Jan. 01, 2017
Share-based Compensation      
Share-based compensation expense before taxes $ 193 $ 164 $ 129
Related income tax benefits (39) (48) (41)
Share-based compensation expense, net of taxes 154 116 88
Cost of product revenue      
Share-based Compensation      
Share-based compensation expense before taxes 16 12 9
Cost of service and other revenue      
Share-based Compensation      
Share-based compensation expense before taxes 3 2 2
Research and development      
Share-based Compensation      
Share-based compensation expense before taxes 60 51 42
Selling, general and administrative      
Share-based Compensation      
Share-based compensation expense before taxes $ 114 $ 99 $ 76
v3.10.0.1
Stockholders' Equity - Summary of Assumptions used to Estimate the Weighted-Average Fair Value Per Share for Stock Purchase under the Employee Stock Purchase Plan (Details) - $ / shares
 12 Months Ended
Dec. 30, 2018
Dec. 31, 2017
Jan. 01, 2017
Assumptions used to estimate the fair value per share of employee stock purchase rights granted      
Expected dividends 0.00%    
Employee stock      
Assumptions used to estimate the fair value per share of employee stock purchase rights granted      
Expected volatility, minimum 29.00% 29.00% 40.00%
Expected volatility, maximum 39.00% 44.00% 44.00%
Expected dividends 0.00% 0.00% 0.00%
Weighted-average grant-date fair value per share (in dollars per share) $ 61.59 $ 46.81 $ 48.29
Employee stock | Minimum      
Assumptions used to estimate the fair value per share of employee stock purchase rights granted      
Risk-free interest rate 1.22% 0.50% 0.40%
Expected term 6 months 6 months 6 months
Employee stock | Maximum      
Assumptions used to estimate the fair value per share of employee stock purchase rights granted      
Risk-free interest rate 2.45% 1.22% 0.50%
Expected term 1 year 1 year 1 year
v3.10.0.1
Stockholders' Equity - Narrative - Share-based Compensation Expense (Details)
$ in Millions
 12 Months Ended
Dec. 30, 2018
USD ($)
Equity [Abstract]  
Unrecognized compensation cost related to restricted stock units and ESPP shares issued to date $ 474
Weighted-average period of unrecognized compensation cost related to restricted stock and ESPP shares issued to date 2 years 6 months
v3.10.0.1
Income Taxes - Summary of Income before Income Taxes by Region (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 30, 2018
Dec. 31, 2017
Jan. 01, 2017
Income Tax Disclosure [Abstract]      
United States $ 54 $ 458 $ 120
Foreign 840 585 441
Income before income taxes $ 894 $ 1,043 $ 561
v3.10.0.1
Income Taxes - Summary of Provision for Income Taxes (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 30, 2018
Dec. 31, 2017
Jan. 01, 2017
Current:      
Federal $ 47 $ 259 $ 71
State 15 21 10
Foreign 68 51 45
Total current provision 130 331 126
Deferred:      
Federal   36 16
State (16)   (5)
Foreign (2) (2) (4)
Total deferred (benefit) expense (18) 34 7
Total tax provision $ 112 $ 365 $ 133
v3.10.0.1
Income Taxes - Summary of Reconciliation of Provision for Income Taxes to Amount Computed by Applying the Federal Statutory Rate (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 30, 2018
Dec. 31, 2017
Jan. 01, 2017
Income Tax Disclosure [Abstract]      
Tax at federal statutory rate $ 188 $ 365 $ 196
State, net of federal benefit 13 19 10
Research and other credits (23) (12) (13)
Change in valuation allowance (12) 12 5
Impact of foreign operations (59) (130) (86)
Cost sharing adjustment     (7)
Investments in consolidated variable interest entities 9 (3) 25
Impact of U.S. Tax Reform 11 150  
Stock compensation (24) (41) 3
Other 9 5  
Total tax provision $ 112 $ 365 $ 133
v3.10.0.1
Income Taxes - Narrative (Details) - USD ($)
$ / shares in Units, $ in Millions
 12 Months Ended
Dec. 30, 2018
Dec. 31, 2017
Jan. 01, 2017
Income Taxes [Line Items]      
Impact of U.S. tax reform $ 11 $ 150  
Increase in provision for income taxes 11    
Transition tax for earnings of certain foreign subsidiaries 108    
Valuation allowance on deferred tax assets 15 25  
Undistributed earnings of foreign subsidiaries 973    
Deferred tax liability 3 5  
Uncertain tax positions that would reduce annual effective tax rate, if recognized 78 70  
Potential interest penalties on uncertain tax positions 3 1 $ 1
Liability recorded for potential interest and penalties $ 11 8  
Foreign | Singapore      
Income Taxes [Line Items]      
Statutory tax rate 17.00%    
Decrease to the provision for income taxes $ 36 $ 49 $ 32
Increase to net income per diluted share $ 0.24 $ 0.33 $ 0.22
Foreign | United Kingdom      
Income Taxes [Line Items]      
Statutory tax rate 19.00%    
Federal | IRS      
Income Taxes [Line Items]      
Net operating loss carryforwards $ 39    
Tax credit carryforwards 1    
State      
Income Taxes [Line Items]      
Net operating loss carryforwards 156    
Tax credit carryforwards 103    
Tax Year 2017      
Income Taxes [Line Items]      
Undistributed earnings of foreign subsidiaries 63    
Deferred tax liability $ 2    
v3.10.0.1
Income Taxes - Summary of Significant Components of Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Millions
Dec. 30, 2018
Dec. 31, 2017
Deferred tax assets:    
Net operating losses $ 26 $ 18
Tax credits 63 57
Other accruals and reserves 28 25
Stock compensation 20 19
Deferred rent 30 28
Cost sharing adjustment 21 21
Other amortization 13 12
Lease obligation 70 27
Investments 1 13
Other 28 26
Total gross deferred tax assets 300 246
Valuation allowance on deferred tax assets (15) (25)
Total deferred tax assets 285 221
Deferred tax liabilities:    
Purchased intangible amortization (32) (26)
Convertible debt (41) (18)
Property and equipment (94) (44)
Investments (45) (40)
Other (3) (5)
Total deferred tax liabilities (215) (133)
Deferred tax assets, net $ 70 $ 88
v3.10.0.1
Income Taxes - Summary of the Gross Amount of Uncertain Tax Positions (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 30, 2018
Dec. 31, 2017
Jan. 01, 2017
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]      
Balance at beginning of year $ 79 $ 65 $ 56
Increases related to prior year tax positions 1 2  
Decreases related to prior year tax positions (1)   (2)
Increases related to current year tax positions 12 14 13
Decreases related to lapse of statute of limitations (3) (2) (2)
Balance at end of year $ 88 $ 79 $ 65
v3.10.0.1
Employee Benefit Plans - Retirement Plan Narrative (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 30, 2018
Dec. 31, 2017
Jan. 01, 2017
Retirement Benefits [Abstract]      
Matching contributions $ 20 $ 17 $ 14
v3.10.0.1
Employee Benefit Plans - Deferred Comp Narrative (Details) - Deferred compensation plan - USD ($)
$ in Millions
 12 Months Ended
Dec. 30, 2018
Dec. 31, 2017
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]    
Employer contribution vesting percent upon the occurrence of participant's disability, death or retirement or change in control of the Company 100.00%  
Deferred compensation plan assets $ 34 $ 35
Deferred compensation liability $ 33 $ 33
Senior level employee    
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]    
Percent of base salary available for contribution to the deferred compensation plan 60.00%  
Percent of all other forms of compensation available for contribution to the deferred compensation plan 100.00%  
Director    
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]    
Percent of all other forms of compensation available for contribution to the deferred compensation plan 100.00%  
v3.10.0.1
Segment Information and Geographic Data - Narrative (Details)
 12 Months Ended
Dec. 30, 2018
segment
Segment Reporting [Abstract]  
Number of reportable segments 2
v3.10.0.1
Segment Information and Geographic Data - Summary of Operating Performance and Assets by Segment (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Dec. 30, 2018
Sep. 30, 2018
Jul. 01, 2018
Apr. 01, 2018
Dec. 31, 2017
Oct. 01, 2017
Jul. 02, 2017
Apr. 02, 2017
Dec. 30, 2018
Dec. 31, 2017
Jan. 01, 2017
Segment Reporting Information [Line Items]                      
Consolidated revenue $ 867 $ 853 $ 830 $ 782 $ 778 $ 714 $ 662 $ 598 $ 3,333 $ 2,752 $ 2,398
Consolidated depreciation and amortization                 179 156 141
Consolidated income from operations                 883 606 587
Consolidated total assets 6,959       5,257       6,959 5,257 4,281
Consolidated capital expenditures                 296 310 260
Operating Segments | Core Illumina                      
Segment Reporting Information [Line Items]                      
Consolidated revenue                 3,334 2,754 2,428
Consolidated depreciation and amortization                 175 153 138
Consolidated income from operations                 970 696 684
Consolidated total assets 6,912       5,223       6,912 5,223 4,167
Consolidated capital expenditures                 294 306 238
Operating Segments | Consolidated VIEs                      
Segment Reporting Information [Line Items]                      
Consolidated revenue                 10 6  
Consolidated depreciation and amortization                 6 6 4
Consolidated income from operations                 (90) (92) (81)
Consolidated total assets 154       45       154 45 180
Consolidated capital expenditures                 2 4 22
Eliminations                      
Segment Reporting Information [Line Items]                      
Consolidated revenue                 (11) (8) (30)
Consolidated depreciation and amortization                 (2) (3) (1)
Consolidated income from operations                 3 2 (16)
Consolidated total assets $ (107)       $ (11)       $ (107) $ (11) $ (66)
v3.10.0.1
Segment Information and Geographic Data - Summary of Net Long-lived Assets Consisting of Property and Equipment by Region (Details) - USD ($)
$ in Millions
Dec. 30, 2018
Dec. 31, 2017
Long-Lived Assets [Line Items]    
Long-lived assets $ 1,075 $ 931
United States    
Long-Lived Assets [Line Items]    
Long-lived assets 907 828
Singapore    
Long-Lived Assets [Line Items]    
Long-lived assets 96 54
United Kingdom    
Long-Lived Assets [Line Items]    
Long-lived assets 62 43
Other countries    
Long-Lived Assets [Line Items]    
Long-lived assets $ 10 $ 6
v3.10.0.1
Quarterly Financial Information (unaudited) - Summary of Quarterly Data (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 12 Months Ended
Dec. 30, 2018
Sep. 30, 2018
Jul. 01, 2018
Apr. 01, 2018
Dec. 31, 2017
Oct. 01, 2017
Jul. 02, 2017
Apr. 02, 2017
Dec. 30, 2018
Dec. 31, 2017
Jan. 01, 2017
Quarterly Financial Information Disclosure [Abstract]                      
Revenue $ 867 $ 853 $ 830 $ 782 $ 778 $ 714 $ 662 $ 598 $ 3,333 $ 2,752 $ 2,398
Gross profit 590 597 575 538 542 482 434 368 2,300 1,826 1,666
Consolidated net income 198 188 200 197 58 152 120 348 782 678 428
Net income attributable to Illumina stockholders $ 210 $ 199 $ 209 $ 208 $ 68 $ 163 $ 128 $ 367 $ 826 $ 726 $ 463
Earnings per share attributable to Illumina stockholders:                      
Basic (in dollars per share) $ 1.43 $ 1.35 $ 1.42 $ 1.42 $ 0.47 $ 1.12 $ 0.87 $ 2.50 $ 5.63 $ 4.96 $ 3.09
Diluted (in dollars per share) $ 1.41 $ 1.33 $ 1.41 $ 1.41 $ 0.46 $ 1.11 $ 0.87 $ 2.48 $ 5.56 $ 4.92 $ 3.07